Apparatus for in-vivo measuring of H2O2 oxidation

ABSTRACT

An apparatus for in-vivo measuring H2O2 oxidation within a living tissue. The apparatus includes an electrochemical probe and an electrochemical stimulator-analyzer. The electrochemical probe includes a sensing part and a handle. The sensing part includes a working electrode, a counter electrode, and a reference electrode. The working electrode includes a first biocompatible conductive needle coated with a layer of vertically aligned multi-walled carbon nanotubes. The counter electrode includes a second biocompatible conductive needle. The reference electrode includes a third biocompatible conductive needle. The electrochemical stimulator-analyzer is configured to generate a set of electrical currents in a portion of the living tissue.

CROSS-REFERENCE TO RELATED APPLICATION

This application is a continuation-in-part of U.S. patent applicationSer. No. 16/857,428, filed Apr. 24, 2020, and entitled “REAL-TIME ANDLABEL FREE ANALYZER FOR IN-VITRO AND IN-VIVO DETECTING THE SUSPICIOUSREGIONS TO CANCER,” which is a continuation-in-part of U.S. patentapplication Ser. No. 16/010,510, filed Jun. 17, 2018, and entitled“REAL-TIME AND LABEL FREE ANALYZER FOR IN-VITRO AND IN-VIVO DETECTINGTHE SUSPICIOUS REGIONS TO CANCER”, which takes priority from U.S.Provisional Patent Application Ser. No. 62/522,115 filed on Jun. 20,2017, and entitled “DIAGNOSIS OF CANCER TUMORS IN BIOPSY BREAST TISSUES”and U.S. Provisional Patent Application Ser. No. 62/563,673 filed onSep. 27, 2017, and entitled “CANCER DIAGNOSTIC PROBE”, which are allincorporated herein by reference in their entirety.

TECHNICAL FIELD

The present disclosure generally relates to cancer diagnosis, andparticularly, to a system, sensor, and method for diagnosing cancerousregions before and during surgery via a real-time and label freeapproach.

BACKGROUND

Glycolysis is the intracellular biochemical conversion of one moleculeof glucose into two molecules of pyruvate, which can be used to attaincellular energy. With the assistance of sufficient oxygen, pyruvatecould be converted by pyruvate dehydrogenase (PDH) into acetylCoA whichis crucial in a metabolizing process to produce ATP in an oxidative way.A physiological concentration of pyruvate in human normal epithelialtissue has been reported to 0.7 mmol/g. Also the lactate-to-pyruvateratio (L/P ratio) as a reflection of cell's redox state, illustrates thebalance between NAD+ and NADH+H+, depending on the interconversion oflactate and pyruvate via lactate dehydrogenase (LDH). The L/P ratio innormal epithelial tissues is less than 20:1. Markers and assays havebeen developed to trace the LADH, P, or L/P in the patients' specimen asdiagnostic or prognostic factors which reveal the interests on lactatebased cancer research. Moreover some methods have been developed totrace pyruvate by electrochemical methods with the assistance ofchemically labelled working electrodes. However, there is still nosubstitutive label free methods and/or devices to replace expensive,complicated, and late-responsive clinical methods and devices such aspathology assays.

Hence, there is a need for cost-effective, label free and real-timemethods and devices, especially sensors and method to use thereof todetect cancer in suspicious regions especially during cancer surgerylike mastectomy to remove involved regions with precise margins toreduce resection of normal sites.

SUMMARY

This summary is intended to provide an overview of the subject matter ofthe present disclosure, and is not intended to identify essentialelements or key elements of the subject matter, nor is it intended to beused to determine the scope of the claimed implementations. The properscope of the present disclosure may be ascertained from the claims setforth below in view of the detailed description below and the drawings.

In one general aspect, the present disclosure describes an exemplaryapparatus for in-vivo measuring H₂O₂ oxidation within a living tissue.An exemplary apparatus may include an electrochemical probe and anelectrochemical stimulator-analyzer. An exemplary electrochemical probemay include a sensing part and a handle. An exemplary sensing part mayinclude a working electrode, a counter electrode, and a referenceelectrode. An exemplary working electrode may include a firstbiocompatible conductive needle coated with a layer of verticallyaligned multi-walled carbon nanotubes (VAMWCNTs). An exemplary counterelectrode may include a second biocompatible conductive needle. Anexemplary reference electrode may include a third biocompatibleconductive needle.

An exemplary handle may include an insertion part and a releasingbutton. In an exemplary embodiment, the insertion part may be attachedto the sensing part. In an exemplary embodiment, the insertion part maybe configured to be inserted into a portion of the living tissue. In anexemplary embodiment, the releasing button may be configured to releasethe sensing part for replacing the sensing part.

In an exemplary embodiment, the electrochemical stimulator-analyzer maybe configured to generate a set of electrical currents in the portion ofthe living tissue by applying a set of electrical potentials to theelectrochemical probe and record the set of electrical currents bymeasuring an electric current flowing from the counter electrode to theworking electrode.

In an exemplary embodiment, the electrochemical stimulator-analyzer maybe further configured to apply the set of electrical potentials byapplying a sweeping range of electrical potentials between −1 V and 1 Vto the working electrode and measure the electric currents at theworking electrode after applying each electrical potential in thesweeping range.

An exemplary electrochemical stimulator-analyzer may include apotentiostat circuit. An exemplary potentiostat circuit may include acontrol amplifier, a transimpedance amplifier, a peak detector circuit,a feedback network, a periodic wave generator, and a comparator circuit.An exemplary control amplifier may include a first control input, asecond control input coupled to the reference electrode, and a controloutput coupled to the counter electrode. In an exemplary embodiment, thecontrol amplifier may be configured to generate a control voltage at thecontrol output by amplifying a voltage difference between the firstcontrol input and the second control input. An exemplary controlamplifier may include an operational amplifier (op-amp).

An exemplary transimpedance amplifier may include a transimpedanceoutput and a transimpedance input connected to the working electrode. Inan exemplary embodiment, the transimpedance amplifier may be configuredto generate a transimpedance voltage at the transimpedance output byamplifying a voltage of the transimpedance input. An exemplary peakdetector circuit may include a detector output and a detector inputcoupled to the transimpedance output. In an exemplary embodiment, thepeak detector circuit may be configured to detect a maximum voltage atthe detector input in a given period of time and transmit the maximumvoltage to the detector output. An exemplary transimpedance amplifiermay include an op-amp.

In an exemplary embodiment, the periodic wave generator may beconfigured to generate a periodic ware at the first control inputresponsive to becoming active. In an exemplary embodiment, the periodicwave generator may be further configured to couple the first controlinput to ground responsive to becoming inactive. An exemplary periodicwave generator may include a pulse wave generator, an op-amp that may becoupled to the pulse wave generator, an RC circuit that may be connectedbetween the op-amp output and the negative input, and a field effecttransistor (FET). An exemplary pulse wave generator may be configured togenerate a periodic rectangular wave. An exemplary op-amp may include apositive input, a negative input, and an op-amp output. In an exemplaryembodiment, the positive input may be connected to ground, the negativeinput may be coupled to an output of the pulse wave generator, and theop-amp output may be connected to the first control input. An exemplaryRC circuit may include a first resistor and a first capacitor that maybe connected in parallel.

An exemplary periodic wave generator may further include a secondresistor and a third resistor. In an exemplary embodiment, the secondresistor may be connected to the negative input and the third resistormay be connected between the second resistor and the output of the pulsewave generator. An exemplary FET may include a source, a drain, and agate. An exemplary source may be connected to ground. In an exemplaryembodiment, the drain may be connected between the second resistor andthe third resistor, and the gate may be connected to the activationinput.

In an exemplary embodiment, the comparator circuit may be configured toactivate the periodic wave generator by providing an activation voltageto an activation input of the periodic wave generator responsive to avoltage of the detector output being smaller than a reference voltage.In an exemplary embodiment, the comparator circuit may be furtherconfigured to deactivate the periodic wave generator by providing adeactivation voltage to the activation input responsive to a voltage ofthe detector output being equal to or larger than the reference voltage.

An exemplary comparator circuit may include a first comparator input, asecond comparator input, and a comparator output. An exemplary firstcomparator input may be connected to the detector output and anexemplary comparator output may be connected to the activation input. Inan exemplary embodiment, the second comparator input may include thereference voltage. An exemplary second comparator input may be coupledto a DC voltage supply that may include a DC voltage. In an exemplaryembodiment, the second comparator input may be coupled to the DC voltagesupply via a variable resistor. An exemplary variable resistor may beconfigured to provide the reference voltage to the second comparatorinput by transmitting a fraction of the DC voltage to the secondcomparator input.

In an exemplary embodiment, the comparator circuit may be configured toprovide the activation voltage to the comparator output responsive to avoltage of the first comparator input being smaller than a voltage ofthe second comparator input and provide the deactivation voltage to thecomparator output responsive to the voltage of the first comparatorinput being equal to or larger than the voltage of the second comparatorinput.

In an exemplary embodiment, the feedback network may be connectedbetween the detector input and the transimpedance input. An exemplaryfeedback network may include a feedback resistor. In an exemplaryembodiment, a resistance R_(f) of the feedback resistor may be equal to

$\frac{V_{ref}}{I_{\max}},$where V_(ref) is the reference voltage and I_(max) is an upper limit ofan electric current flowing through the detector input.

In an exemplary embodiment, the potentiostat circuit may further includea unity gain amplifier that may be connected between the referenceelectrode and the second control input. An exemplary unity gainamplifier may include a first unity gain input, a unity gain output, anda second unity gain input. In an exemplary embodiment, the first unitygain input may be connected to the reference electrode, the unity gainoutput may be connected to the second control input, and the secondunity gain input may be connected to the unity gain output. In anexemplary embodiment, the unity gain amplifier may be configured totransmit a voltage at the reference electrode to the unity gain outputby amplifying a voltage difference between the first unity gain inputand the second unity gain input. An exemplary unity gain amplifier mayinclude an op-amp.

In an exemplary embodiment, the potentiostat circuit may further includea first current buffer amplifier (CBA) that may be connected between thecontrol amplifier and the counter electrode. An exemplary first CBA maybe configured to transfer an electric current flowing through thecontrol output to the counter electrode. In an exemplary embodiment, thepotentiostat circuit may further include a second CBA that may beconnected between the transimpedance amplifier and the peak detectorcircuit. An exemplary second CBA may be configured to transfer anelectric current flowing through the transimpedance output to thedetector input.

In an exemplary embodiment, the potentiostat circuit may further includea first analog compensator that may be connected between the counterelectrode and the first control input. An exemplary first analogcompensator may be configured to compensate voltage variations at thecounter electrode responsive to voltage variations at the first controlinput. An exemplary first analog compensator may include a firstcompensation capacitor. In an exemplary embodiment, the potentiostatcircuit may further include a second analog compensator that may beconnected between the second control input and ground. An exemplarysecond analog compensator may be configured to compensate voltagevariations at the second control input. An exemplary second analogcompensator may include a second compensation capacitor and acompensation resistor that may be connected in series.

In an exemplary embodiment, each of the first biocompatible conductiveneedle, the second biocompatible conductive needle, and the thirdbiocompatible conductive needle may include a respective sensing tipcoated with a layer of VAMWCNTs. In an exemplary embodiment, each of theworking electrode, the counter electrode, and the reference electrodemay include a respective sensing tip with a diameter between 100 μm and200 μm, and a length between 0.1 cm and 1 cm. In an exemplaryembodiment, the working electrode, the counter electrode, and thereference electrode may be attached to the insertion part at one end ofthe handle apart from each other with a distance between 1 mm and 5 mm.

In an exemplary embodiment, the sensing part may further include anelectrode holder encompassing the working electrode, the counterelectrode, and the reference electrode. In an exemplary embodiment, thehandle may further include a handle head and a switch located on thehandle head. In an exemplary implementation, the switch may beconfigured to connect the electrochemical probe to an electrochemicalstimulator-analyzer device, and disconnect the electrochemical probefrom the electrochemical stimulator-analyzer device.

Other exemplary systems, methods, features and advantages of theimplementations will be, or will become, apparent to one of ordinaryskill in the art upon examination of the following figures and detaileddescription. It is intended that all such additional systems, methods,features and advantages be included within this description and thissummary, be within the scope of the implementations, and be protected bythe claims herein.

BRIEF DESCRIPTION OF THE DRAWINGS

The drawing figures depict one or more implementations in accord withthe present teachings, by way of example only, not by way of limitation.In the figures, like reference numerals refer to the same or similarelements.

FIG. 1A illustrates a schematic view of an exemplary electrochemicalsystem for cancer diagnosis, consistent with one or more exemplaryembodiments of the present disclosure.

FIG. 1B illustrates a schematic view of an exemplary CNT basedelectrochemical chip, consistent with one or more exemplary embodimentsof the present disclosure.

FIG. 1C illustrates a schematic view of an exemplary sensing well,consistent with one or more exemplary embodiments of the presentdisclosure.

FIG. 1D illustrates a schematic view of an exemplary magnified portionof exemplary working electrode within exemplary sensing well of FIG. 1C,consistent with one or more exemplary embodiments of the presentdisclosure.

FIG. 1E illustrates a schematic view of an exemplary cancer diagnosisprobe (CDP), consistent with one or more exemplary embodiments of thepresent disclosure.

FIG. 1F illustrates a schematic view of an exemplary needle electrode ofexemplary CDP corresponding to the working electrode, consistent withone or more exemplary embodiments of the present disclosure.

FIG. 1G illustrates a schematic view of an exemplary magnified portionof a tip of exemplary needle electrode of FIG. 1C, consistent with oneor more exemplary embodiments of the present disclosure.

FIG. 1H illustrates a schematic view of another implementation of anexemplary cancer diagnosis probe (CDP) for in-vivo measurement of H₂O₂oxidation in a living tissue, consistent with one or more exemplaryembodiments of the present disclosure.

FIG. 1I illustrates a schematic view of an exemplary scenario in whichan exemplary sensing part has been separated from an exemplary handle ofan exemplary CDP, consistent with one or more exemplary embodiments ofthe present disclosure.

FIG. 1J illustrates a schematic view of an exemplary working electrode,consistent with one or more exemplary embodiments of the presentdisclosure.

FIG. 1K shows a schematic of a first implementation of a potentiostatcircuit, consistent with one or more exemplary embodiments of thepresent disclosure.

FIG. 1L shows a schematic of a periodic wave generator, consistent withone or more exemplary embodiments of the present disclosure.

FIG. 1M shows a schematic of a second implementation of a potentiostatcircuit, consistent with one or more exemplary embodiments of thepresent disclosure.

FIG. 1N shows a computer system in which an embodiment of the presentdisclosure, or portions thereof, may be implemented as computer-readablecode, consistent with exemplary embodiments of the present disclosure.

FIG. 2A illustrates an exemplary implementation of a method for cancerdiagnosis, consistent with one or more exemplary embodiments of thepresent disclosure.

FIG. 2B illustrates a schematic implementation of putting the array ofvertically aligned multi-walled carbon nanotubes (VAMWCNTs) grown on tipof each needle electrode of three needles electrodes of exemplary CDP incontact with exemplary suspicious sample, consistent with one or moreexemplary embodiments of the present disclosure.

FIG. 2C illustrates a schematic view of another exemplary implementationof putting exemplary electrodes of exemplary CDP in contact with anexemplary portion of a living tissue, consistent with one or moreexemplary embodiments of the present disclosure.

FIG. 2D illustrates an implementation of detecting the cancerous statein the suspicious sample, consistent with one or more exemplaryembodiments of the present disclosure.

FIG. 2E illustrates an exemplary implementation of an exemplary methodfor in-vivo cancer diagnosis within a living tissue, consistent with oneor more exemplary embodiments of the present disclosure.

FIG. 2F illustrates an exemplary implementation of preparing anexemplary electrochemical probe similar to the exemplary CDP, consistentwith one or more exemplary embodiments of the present disclosure.

FIG. 2G illustrates an exemplary implementation of fabricating threeintegrated electrodes by coating a layer of vertically alignedmulti-walled carbon nanotubes (VAMWCNTs) on tips of three electricallyconductive biocompatible needles, consistent with one or more exemplaryembodiments of the present disclosure.

FIG. 2H illustrates an exemplary implementation of growing an array ofVAMWCNTs on exemplary deposited catalyst layer, consistent with one ormore exemplary embodiments of the present disclosure.

FIG. 2I shows an exemplary implementation of detecting thecancer-involving status of the exemplary portion of the exemplary livingtissue based on the oxidation current peak, consistent with one or moreexemplary embodiments of the present disclosure.

FIG. 2J shows an exemplary implementation of generating a set ofreference current peak values, consistent with one or more exemplaryembodiments of the present disclosure.

FIG. 3A illustrates a schematic view of exemplary electrochemicalreactions involved on sensor including exemplary VAMWCNTs as shown inFIGS. 1D and 1G, consistent with one or more exemplary embodiments ofthe present disclosure.

FIG. 3B illustrates a schematic overview of mitochondrial electron andproton fluxes in hypoxia, consistent with one or more exemplaryembodiments of the present disclosure.

FIG. 4 illustrates a field emission scanning electron microscopy (FESEM)image of the VAMWCNTs array on a portion of an exemplary fabricated CNTbased electrochemical chip, consistent with one or more exemplaryembodiments of the present disclosure.

FIG. 5A illustrates a FESEM image of a tip of a needle electrode of anexemplary fabricated cancer diagnostic probe (CDP) coated with an arrayof VAMWCNTs on the tip, consistent with one or more exemplaryembodiments of the present disclosure.

FIG. 5B illustrates a FESEM image of a first portion of an exemplaryVAMWCNTs array grown on the tip of the needle electrode of exemplaryfabricated CDP, consistent with one or more exemplary embodiments of thepresent disclosure.

FIG. 5C illustrates a FESEM image of a second portion of an exemplaryVAMWCNTs array grown on the tip of the needle electrode of exemplaryfabricated CDP, consistent with one or more exemplary embodiments of thepresent disclosure.

FIG. 5D illustrates a FESEM image of a third portion of an exemplaryVAMWCNTs array grown on the tip of the needle electrode of exemplaryfabricated CDP, consistent with one or more exemplary embodiments of thepresent disclosure.

FIG. 6A illustrates the CV diagrams of L-lactic acid solutionindividually recorded by electrochemical sensors fabricated fromplatinum (Pt), Gold (Au), amorphous glassy carbon (GC) and carbonnanotube (CNT) working electrodes (WEs), consistent with one or moreexemplary embodiments of the present disclosure.

FIG. 6B illustrates the CV diagrams of solutions with variousconcentrations of Hydrogen Peroxide (H₂O₂) resulted from the lactateturn to H₂O₂ and pyruvate recorded by electrochemical sensors with CNTarrays working electrode, consistent with one or more exemplaryembodiments of the present disclosure.

FIG. 6C illustrates the CV diagrams of H₂O₂ contained lactate solutionin comparison with two cell culture solutions recorded byelectrochemical sensors with CNT arrays working electrode, consistentwith one or more exemplary embodiments of the present disclosure.

FIG. 7 illustrates the CV diagrams of hypoxic glycolysis in MCF 10A,MCF-7, MDA-MB-231, and MDA-MB-468 cell lines in comparison with H₂O₂contained lactate solution and RPMI measured and recorded by exemplaryCNT based electrochemical chip, consistent with one or more exemplaryembodiments of the present disclosure.

FIG. 8A illustrates the CV responses of the solution media of differentnormal and cancerous cell lines in various phenotypes for Colon (COR-L105, SW-480, HT-29) cell lines in comparison with Reference diagram forsolution H₂O₂ contained solution with a lactate concentration of about0.3 mM, consistent with one or more exemplary embodiments of the presentdisclosure.

FIG. 8B illustrates the CV responses of the solution media of differentnormal and cancerous cell lines in various phenotypes for Hematopoietic(1301, LCL-P11) cell lines in comparison with Reference diagram for H₂O₂contained solution with a lactate concentration of about 0.3 mM,consistent with one or more exemplary embodiments of the presentdisclosure.

FIG. 8C illustrates the CV responses of the solution media of differentnormal and cancerous cell lines in various phenotypes for Liver (HEP G2)cell lines in comparison with Reference diagram for H₂O₂ containedlactate solution with a lactate concentration of about 0.3 mM,consistent with one or more exemplary embodiments of the presentdisclosure.

FIG. 8D illustrates the CV responses of the solution media of differentnormal and cancerous cell lines in various phenotypes for Lung (QU-DB,MRC-5) cell lines in comparison with Reference diagram for H₂O₂contained lactate solution with a lactate concentration of about 0.3 mM,consistent with one or more exemplary embodiments of the presentdisclosure.

FIG. 8E illustrates the CV responses of the solution media of differentnormal and cancerous cell lines in various phenotypes for Mouth (KB)cell lines in comparison with Reference diagram for H₂O₂ containedlactate solution with a lactate concentration of about 0.3 mM,consistent with one or more exemplary embodiments of the presentdisclosure.

FIG. 8F illustrates the CV responses of the solution media of differentnormal and cancerous cell lines in various phenotypes for Neuron(BE(2)-C, LAN-5) cell lines in comparison with Reference diagram forH₂O₂ contained lactate solution with a lactate concentration of about0.3 mM, consistent with one or more exemplary embodiments of the presentdisclosure.

FIG. 8G illustrates the CV responses of the solution media of differentnormal and cancerous cell lines in various phenotypes for Prostate(PC-3, Du-145) cell lines in comparison with Reference diagram for H₂O₂contained lactate solution with a lactate concentration of about 0.3 mM,consistent with one or more exemplary embodiments of the presentdisclosure.

FIGS. 9A-9F illustrate the cytopathological results (top side) andelectrochemical responses (bottom side) of the breast tissues removed bybiopsy or surgery from 6 suspicious patients to cancer, consistent withone or more exemplary embodiments of the present disclosure.

FIG. 10 illustrates a columnar diagram of electrochemical responses ofthe breast tissues removed by biopsy or surgery from 11 suspiciouspatients to cancer, consistent with one or more exemplary embodiments ofthe present disclosure.

FIG. 11A illustrates CV response of exemplary CDP with all three needlescovered by VAMWCNTs immediately after connection to the tissues,consistent with one or more exemplary embodiments of the presentdisclosure.

FIG. 11B illustrates CV response of exemplary CDP with only workingelectrode covered by VAMWCNTs immediately after connection to thetissues, consistent with one or more exemplary embodiments of thepresent disclosure.

FIG. 11C illustrates CV response of exemplary CDP with non-CNT coveredby needles immediately after connection to the tissues, consistent withone or more exemplary embodiments of the present disclosure.

FIGS. 12A-12E illustrate CV responses recorded by exemplary CDP (needlebased electrochemical sensor) from the resected tissues from fivepatients among 50 individual patients suspicious to breast cancer(bottom side) in comparison with images obtained by conventionalpathological methods (H&E) (top side), consistent with one or moreexemplary embodiments of the present disclosure.

FIG. 13 illustrates a summary of categorized regimes of CV responsesrecorded by exemplary CDP from the resected tissues from five patientsamong 50 individual patients suspicious to breast cancer representing CVregimes along a spectrum from a completely non-cancerous state tocancerous state, consistent with one or more exemplary embodiments ofthe present disclosure.

FIG. 14A illustrates a sonography image from a tumor side taken from anexemplary mouse tumorized by 4T1 breast cancer cell lines, consistentwith one or more exemplary embodiments of the present disclosure.

FIG. 14B illustrates H&E image from the tumor side taken from exemplarytumorized mouse by 4T1 breast cancer cell lines, consistent with one ormore exemplary embodiments of the present disclosure.

FIG. 14C illustrates H&E image from a normal/healthy side taken fromexemplary tumorized mouse by 4T1 breast cancer cell lines, consistentwith one or more exemplary embodiments of the present disclosure.

FIG. 14D illustrates CV diagrams of normal and tumor regions/sides ofexemplary tumorized mouse by 4T1 breast cancer cell lines calibrated bya Reference CV diagram from H₂O₂ contained lactate solution with alactate concentration of about 0.3 mM obtained using exemplary CDP,consistent with one or more exemplary embodiments of the presentdisclosure.

FIG. 15A illustrates a sonography image from a tumor taken from anexemplary mouse tumorized by 4T1 breast cancer cell lines, consistentwith one or more exemplary embodiments of the present disclosure.

FIG. 15B illustrates exemplary six analyzed regions of an exemplarytumorized mouse among the exemplary five tumorized mice before surgery,consistent with one or more exemplary embodiments of the presentdisclosure.

FIG. 15C illustrates exemplary six analyzed regions of an exemplarytumorized mouse among the exemplary five tumorized mice during surgery,consistent with one or more exemplary embodiments of the presentdisclosure.

FIG. 16 illustrates comparative diagram of CDP responses in interactionwith normal, nonmalignant tumor, and malignant tumor recorded fromindividual mice, consistent with one or more exemplary embodiments ofthe present disclosure.

FIG. 17A illustrates CV response diagram obtained by applying exemplaryCDP in detection of suspicious margins during breast cancer surgery fora known normal region, consistent with one or more exemplary embodimentsof the present disclosure.

FIG. 17B illustrates CV response diagram obtained by applying exemplaryCDP in detection of suspicious margins during breast cancer surgery fora suspicious region, consistent with one or more exemplary embodimentsof the present disclosure.

FIG. 17C illustrates CV response diagram obtained by applying exemplaryCDP in detection of suspicious margins during breast cancer surgery foranother suspicious region, consistent with one or more exemplaryembodiments of the present disclosure.

FIG. 17D illustrates an H&E resulted image after the surgery for a knownnormal region, consistent with one or more exemplary embodiments of thepresent disclosure.

FIG. 17E illustrates an H&E resulted image after the surgery for asuspicious region, consistent with one or more exemplary embodiments ofthe present disclosure.

FIG. 17F illustrates an H&E resulted image after the surgery for anothersuspicious region, consistent with one or more exemplary embodiments ofthe present disclosure.

FIG. 18 illustrates I&E images from nine exemplary samples, consistentwith one or more exemplary embodiments of the present disclosure.

FIG. 19 illustrates classification of current peaks recorded byexemplary CDP after examining more than 250 samples in consistence withpathological diagnosis, consistent with one or more exemplaryembodiments of the present disclosure.

FIG. 20A illustrates an image resulted from frozen I&E (top-side image),an image resulted from permanent H&E (middle-side image), and a CVresponse recorded by exemplary CDP (bottom-side image) for the anteriorIM of a patient (ID 18), consistent with one or more exemplaryembodiments of the present disclosure.

FIG. 20B illustrates an image resulted from frozen H&E (top-side image),an image resulted from permanent H&E (middle-side image), and a CVresponse recorded by exemplary CDP (bottom-side image) for a suspiciousmargin inside the body of the patient (anterior margin of patient ID46), consistent with one or more exemplary embodiments of the presentdisclosure.

FIG. 20C illustrates an image resulted from frozen H&E (top-side image),an image resulted from permanent H&E (middle-side image), and a CVresponse recorded by exemplary CDP (bottom-side image) for a suspiciousmargin inside the body of the patient (posterior IM of patient ID 46),consistent with one or more exemplary embodiments of the presentdisclosure.

FIG. 20D illustrates an image resulted from frozen H&E (top-side image),an image resulted from permanent H&E (middle-side image), and a CVresponse recorded by exemplary CDP (bottom-side image) for SentinelLymph Node (SLN) of patient ID 18, consistent with one or more exemplaryembodiments of the present disclosure.

FIG. 21 illustrates a visually summarized comparison between currentpeak values of recorded CV responses utilizing the exemplary CDP viaexemplary methods for in-vivo cancer diagnosis within a living tissue,and CIN pathological classification, consistent with one or moreexemplary embodiments of the present disclosure.

DETAILED DESCRIPTION

In the following detailed description, numerous specific details are setforth by way of examples in order to provide a thorough understanding ofthe relevant teachings. However, it should be apparent that the presentteachings may be practiced without such details. In other instances,well known methods, procedures, components, and/or circuitry have beendescribed at a relatively high-level, without detail, in order to avoidunnecessarily obscuring aspects of the present teachings. The followingdetailed description is presented to enable a person skilled in the artto make and use the methods and devices disclosed in exemplaryembodiments of the present disclosure. For purposes of explanation,specific nomenclature is set forth to provide a thorough understandingof the present disclosure. However, it will be apparent to one skilledin the art that these specific details are not required to practice thedisclosed exemplary embodiments. Descriptions of specific exemplaryembodiments are provided only as representative examples. Variousmodifications to the exemplary implementations will be readily apparentto one skilled in the art, and the general principles defined herein maybe applied to other implementations and applications without departingfrom the scope of the present disclosure. The present disclosure is notintended to be limited to the implementations shown, but is to beaccorded the widest possible scope consistent with the principles andfeatures disclosed herein.

A number of current methods utilize lactate and/or pyruvate as cancermarkers. However, herein the oxidation of Hydrogen Peroxide (H₂O₂)molecules measured by carbon nanotubes (CNTs) based electrodes isutilized to detect cancer and especially distinguish cancerous regionsfrom healthy regions in a suspicious tissue. The main consequence ofpyruvate formation from lactate is release of H₂O₂ molecules as the mainbyproduct of hypoxia glycolysis. An abnormal redox state appears incancer cells based on modulation of hypoxia with increased pyruvateconcentration and lactate-to-pyruvate ratio (UP ratio) which results inincreasing the concentration of H₂O₂ in interstitial fluid (stroma). So,determination of H₂O₂ molecules would be an indication for the presenceof cancer cells in a tissue. As H₂O₂ is an active and non-stablemolecule it would turn to O₂, H₄ and release electrons which are greattarget charges for electrochemical sensation.

Herein, an electrochemical approach based on multi-walled carbonnanotubes (MWCNTs) electrodes is disclosed for fast tracking of hypoxiaglycolysis in the interstitial fluid of biopsied tissues suspicious tocancer, such as breast tissues. Electrochemical reduction of H₂O₂molecules, produced in lactate to pyruvate transformation, on theelectrodes of disclosed system may present a significant quantitateresponse signal in correlation with the presence of cancer cells in asuspicious sample. Here, a cancer diagnostic probe (CDP) based onvertically aligned multi-walled carbon nanotubes (VAMWCNTs) arrays assensing electrode with direct and selective electron transfer abilitiesin interaction with H₂O₂ may be utilized.

Disclosed herein may include a label free method for diagnosis of thepresence of cancer in suspicious regions based on determination of thehypoxia glycolysis in a quantitative manner. The method may be based onmeasuring the oxidative currents released during glycolysis from thetissue. A matched diagram between an electrochemical response measuredfrom a suspicious sample and cancerous state curves may be utilized fora final diagnostic result. Over expression of glycolysis assisted mRNAsin cancerous samples may be observed as an indicator of a presence ofcancer in a sample. Exemplary method may be applied as an alternativefor frozen pathology during the surgery with faster and more preciseefficiency. Furthermore, a label free system including anelectrochemical sensor with integrated three CNT based electrodes isdisclosed for tracking hypoxia glycolysis via detecting electrochemicalreduction of H₂O₂ molecules, which may be produced in Lactate topyruvate transformation in cancer cells. Exemplary simple and label freeelectrochemical assay may also be used for measuring the drug resistanceof the tumors as a pre therapeutic prediction (as a new prognosticfactor) to increase the survival rate in future.

In some implementations, exemplary electrochemical sensor may include anintegrated sensor on the needles, named herein as a cancer diagnosticprobe (CDP). Exemplary CDP may be fabricated and utilized in real-timeon the suspicious regions to cancer before and during surgery inpatients (In vivo). The domain of suspicious regions with a resolutionof about 3 mm may be detected using exemplary method and CDP. Thesignificant specification of CDP rather than recently reported real-timediagnostic methods, such as mass-spec, may allow the CDP to track thecancer involved regions before surgery by squeezing exemplary CDP tosuspicious regions through the skin with the tracking resolution of 3mm. In conventional diagnostic protocols, to precisely remove the cancerregions during surgery, a frozen sample from each suspicious region mayneed to be sent for pathologists. The pathology results may be availableafter about 15 minutes with the false negative response ratio of about10%. Whereas, a cancer region may be distinguished in-situ utilizingexemplary CDP in less than about 10 seconds or even instantaneouslybefore or during surgery and without any need for resecting and freezinga sample from a patient. The diagnostic information obtained byexemplary CDP may be used to detect cancer in marginally suspiciousregions with rare distributions of cancer cells filtrated between normalstroma in less than about 20 seconds during the surgery or biopsy oflive animal or human models without any requirement of tissue resectionand preparation for frozen pathology. Exemplary CDP may be also utilizedto detect an accurate location of cancer involved regions before surgeryin superficial tumors.

Moreover, exemplary sensor may include a CNT based electrochemical chipfor in vitro cancer diagnosis in suspicious samples. Exemplary CNT basedelectrochemical chip may include an array of electrodes of VAMWCNTs usedin electrochemical assays. Both liquid and solid suspicious samples maybe analyzed using exemplary CNT based electrochemical chip to detect acancer presence within the suspicious samples.

FIG. 1A shows a schematic view of an electrochemical system 100 forcancer diagnosis, consistent with one or more exemplary embodiments ofthe present disclosure.

Exemplary electrochemical system 100 may include an exemplary sensor102, an electrochemical stimulator-analyzer 104, and an array ofelectrically conductive connectors 106. Exemplary sensor 102 may beconfigured to put in contact with a suspicious sample for cancer.Exemplary sensor 102 may include an integrated three-electrodes array,which may include the working electrode 108, the counter electrode 110,and the reference electrode 112. Each of the working electrode 108, thecounter electrode 110 and the reference electrode 112 may include anarray of vertically aligned multi-walled carbon nanotubes (VAMWCNTs).The electrochemical stimulator-analyzer 104 may be configured to measureelectrochemical responses from the working electrode 108 and sensor 102may be connected to the electrochemical stimulator-analyzer 104 via thearray of electrically conductive connectors 106.

In an exemplary implementation, exemplary electrochemical system 100 maybe configured to detect a cancerous state via measuring H₂O₂ duringhypoxia glycolysis in the suspicious sample for cancer. Exemplaryelectrochemical system 100 may be utilized by an exemplary method forcancer diagnosis described herein below.

In an exemplary embodiment, electrochemical stimulator-analyzer 104 mayinclude a device that may be capable of measuring cyclic voltammetry(CV) based diagrams. In an exemplary embodiment, electrochemicalstimulator-analyzer 104 may include a potentiostat.

In an exemplary implementation, electrochemical system 100 may furtherinclude a processor 114 that may be utilized for recording and analyzingelectrochemical measurements that may be measured by electrochemicalstimulator-analyzer 104. Processor 114 may also be used for controllingelectrochemical stimulations that may be carried out by electrochemicalstimulator-analyzer 104. In an exemplary embodiment, processor 114 mayinclude an EVIUM readout system.

In an exemplary implementation, sensor 102 may include a CNT basedelectrochemical chip that may be configured to conduct in vitro cancerdiagnosis assays. FIG. 1B shows a schematic view of exemplary CNT basedelectrochemical chip 102, consistent with one or more exemplaryembodiments of the present disclosure. Exemplary CNT basedelectrochemical chip 102 may include at least one sensing well 120 andone array of electrically conductive connectors 106. FIG. 1C shows aschematic view of exemplary sensing well 120, consistent with one ormore exemplary embodiments of the present disclosure. Each sensing well120 may include a substrate 122, a passivation layer 124 that may begrown on substrate 122, a catalyst layer 126 that may be coated ordeposited and subsequently patterned on the passivation layer 124, andthree arrays of VAMWCNTs that may be grown on the catalyst layer 126.Three arrays of VAMWCNTs may include the working electrode 108, thecounter electrode 110, and the reference electrode 112.

In an exemplary embodiment, substrate 122 may include a silicon chip orwafer. Passivation layer 124 may include a layer of SiO₂ with athickness of less than about 500 nm that may be grown by wet oxidationfurnace on the surface of on substrate 122. Catalyst layer 126 mayinclude a layer of Nickel (Ni) with a thickness of less than about 10 nmthat may be coated on passivation layer 124 by an E-beam evaporationsystem at a temperature of about 120° C. with depositing rate of about0.1 Angstroms/s. Three arrays of VAMWCNTs (the working electrode 108,the counter electrode 110, and the reference electrode 112) may be grownon catalyst layer 126 using a direct current plasma enhanced chemicalvapor deposition (DC-PECVD) system. The growth process of VAMWCNTs mayinclude three steps of firstly, annealing at a temperature of about 680°C. in an H₂ environment with a flow rate of about 35 standard cubiccentimeters per minute (sccm) for about 30 minutes; secondly, graining,including plasma hydrogenation of surface for about 5 minutes with theintensity of about 5.5 W·cm⁻² that may result in the catalyst layer 126graining and formation of Ni nano-sized islands, and finally, growth ofVAMWCNTs by introducing a plasma of C₂H₂ and H₂ mixture with flow ratesof about 5 sccm and about 35 sccm to the chamber for about 15 minutes.Each of the VAMWCNTs may have a length between about 0.5 μm and about 5μm and a diameter between about 20 nm and about 100 nm. The workingelectrode 108 may be grown on an area of about 1 cm×1 cm, the counterelectrode 110 may be grown on an area of about 1 cm×1 cm, and thereference electrode 112 may be grown on an area of about 0.5 cm×0.5 cm.

FIG. 1D shows a schematic view of an exemplary magnified portion 128 ofexemplary working electrode 108 within exemplary sensing well 120 ofFIG. 1C, consistent with one or more exemplary embodiments of thepresent disclosure. Exemplary VAMWCNTs 130 of an array of VAMWCNTs ofworking electrode 108 may be grown vertically on catalyst layer 126.Catalyst layer 126 may be coated or deposited and subsequently patternedon the passivation layer 124, where passivation layer 124 may be grownon substrate 122.

In an exemplary implementation, sensor 102 may include a cancerdiagnosis probe (CDP) that may be configured to conduct in vivo cancerdiagnosis assays. FIG. 1E shows a schematic view of exemplary cancerdiagnosis probe (CDP) 102, consistent with one or more exemplaryembodiments of the present disclosure. Exemplary cancer diagnosis probe(CDP) may include three needle electrodes 132, 134, and 136 as exemplaryimplementations of the working electrode 108, the counter electrode 110,and the reference electrode 112, respectively. Moreover, CDP 102 mayinclude a holding member 138 that may be configured to hold three needleelectrodes 132, 134, and 136. Three needle electrodes 132, 134, and 136may be fixed on one end 140 of the holding member 138.

FIG. 1F shows a schematic view of an exemplary needle electrode 132corresponding to the working electrode 108, consistent with one or moreexemplary embodiments of the present disclosure. Referring to FIG. 1F,each needle electrode of three needles electrodes 132, 134, and 138 mayinclude a tip 142. Each needle electrode of the three needles electrodes132, 134, and 136 may include a catalyst layer 144 that may be depositedon tips 142 of three needles electrodes 132,134, and 136 and an array ofVAMWCNTs 146 that may be grown on catalyst layer 144 on tip 142 of eachneedle electrode of three needles electrodes 132, 134, and 138.

In an exemplary embodiment, each needle electrode of three needleselectrodes 132, 134, and 138 may include a steel needle with a diameterbetween about 100 μm and about 200 μm, and a length between about 0.1 cmand about 1 cm. Three needle electrodes 132, 134, and 138 may be fixedon the end 140 of the holding member 138 apart from each other with adistance (interspace) between each other in a range of about 1 mm toabout 5 mm.

In an exemplary embodiment, catalyst layer 144 may include a layer ofNickel (Ni) with a thickness of less than about 10 nm that may be coatedon tip 142 of each needle electrode by an E-beam evaporation system at atemperature of about 120° C. with a depositing rate of about 0.1Angstroms/s. Three arrays of VAMWCNTs (the working electrode 108, thecounter electrode 110, and the reference electrode 112) may be grown oncatalyst layer 144 using a direct current plasma enhanced chemical vapordeposition (DC-PECVD) system as described herein above.

FIG. 1G shows a schematic view of an exemplary magnified portion 148 oftip 142 of exemplary needle electrode 132 shown in FIG. 1F, consistentwith one or more exemplary embodiments of the present disclosure.Exemplary VAMWCNTs 130 of an array of VAMWCNTs 146 may be grownvertically on catalyst layer 144. Catalyst layer 144 may be coated ordeposited on a surface of tip 142.

Exemplary cancer diagnosis probe (CDP) 102 may have variousimplementations. Exemplary cancer diagnosis probe (CDP) 102 may includean electrochemical probe with three integrated needle-shaped electrodesfor in-vivo electrochemical measurements and diagnosis operations, suchas cancer diagnostic techniques or methods. FIG. 1H shows a schematicview of another implementation of exemplary cancer diagnosis probe (CDP)102 for in-vivo measurement of H₂O₂ oxidation in a living tissue,consistent with one or more exemplary embodiments of the presentdisclosure. Exemplary CDP 102 may be utilized for in-vivo measurement ofH₂O₂ oxidation in a living tissue; thereby, allowing for detecting acancerous state within the living tissue. Exemplary CDP 102 may includea handle 152 and a sensing part 154, where sensing part 154 may beattached to a first end 156 of handle 152. Exemplary sensing part 154may include an exemplary working electrode 158, an exemplary counterelectrode 160, and an exemplary reference electrode 162. Exemplarysensing part 154 may further include an electrode holder 164. In anexemplary embodiment, each of exemplary working electrode 158, counterelectrode 160, and reference electrode 162 may be attached to electrodeholder 164.

In an exemplary embodiment, handle 152 may include a handle head 166, aninsertion part 168, a switch 170, and a releasing button 172. Exemplaryinsertion part 168 may allow for inserting CDP 102 into a biologicalsample, for example, an exemplary living tissue in a patient's body, atumor in a patient's body, or a biopsied sample from a patient who mayinvolve with cancer. Exemplary switch 170 may be located on head 166 andswitch 170 may be configured to connect CDP 102 to an electrochemicalstimulator-analyzer device and/or disconnect CDP 102 from theelectrochemical stimulator-analyzer device. In an exemplary embodiment,the electrochemical stimulator-analyzer device may include apotentiostat device or an electrochemical workstation.

In an exemplary embodiment, CDP 102 may be connected to anelectrochemical stimulator-analyzer device through an electricalconnector, for example, an electrical wire, that may be connected to asecond end 174 of handle 152. In another exemplary embodiment, CDP 102may be connected to the electrochemical stimulator-analyzer deviceutilizing a wireless connection between CDP 102 and the electrochemicalstimulator-analyzer device without any needs to connecting wires. Forexample, CDP 102 may be connected to the electrochemicalstimulator-analyzer device via Bluetooth devices or Bluetooth modulesthat may be embedded in CDP 102 and the electrochemicalstimulator-analyzer device. The wireless connection may allow forsimplifying utilizing CDP 102 in a surgery room by a surgeon, removingredundant wires that may require to sanitize iteratively, etc.

In an exemplary embodiment, sensing part 154 may be replaceable byreleasing from handle 152 using releasing button 172. Althoughelectrochemical measurements that may be carried out utilizing CDP 102may be repeatable, sensing part 154 may be replaced by another sensingpart 154 (a fresh/new sensing part 154) for each insertion into eachpart of the biological sample, which may be an obligation regardingmedical ethics. Such obligations may be mandatory to avoid transferringcancer cells from one part of the biological sample to another part ofthe biological sample; i.e., from one part of a patient's body toanother part of a patient's body. In an exemplary embodiment, sensingpart 154 may be attached to insertion part 168 at the first end 156 ofhandle 152. Furthermore, releasing button 172 may be located oninsertion part 168 in proximity to the first end 156 of handle 152.Exemplary sensing part 154 may be separated from handle 152 by pressingreleasing button 172. FIG. 1I shows a schematic view of an exemplaryscenario in which sensing part 154 has been separated from handle 152 ofexemplary CDP 102, consistent with one or more exemplary embodiments ofthe present disclosure.

Referring to FIG. 1H, exemplary CDP 102 may include three exemplaryelectrodes including working electrode 158, counter electrode 160, andreference electrode 162. In an exemplary embodiment, working electrode158 may comprise of a first needle coated with a layer of VAMWCNTs (anarray of VAMWCNTs). VAMWCNTs may be great sensitive agents for sensingand measuring H₂O₂ as well as high electrically conductive agents foraccurate electrochemical measurements. Exemplary counter electrode 160may comprise of a second needle, and exemplary reference electrode 162may comprise of a third needle. In an exemplary embodiment, the secondneedle may be coated with a layer of VAMWCNTs (an array of VAMWCNTs). Inanother exemplary embodiment, the third needle may be coated with alayer of VAMWCNTs (an array of VAMWCNTs).

In an exemplary embodiment, working electrode 158, counter electrode160, and reference electrode 162 may be located apart from each otherwith a distance between each two respective electrodes of between about1 mm and about 5 mm. In an exemplary embodiment, the distance betweeneach two respective electrodes may be more than about 5 mm. It should benoted that the distance between each two respective electrodes may beselected depending on size of a sample, in which exemplary CDP 102 maybe inserted. The distance between each two respective electrodes may beselected less than about 5 mm in order to obtain high-accurateelectrochemical responses (i.e., CV diagrams) from the sample. Inaddition, the distance between each two respective electrodes should notbe selected may be selected more than about 1 mm in order to avoidelectrical noise in electrochemical measurements.

In an exemplary embodiment, each of the first needle, the second needle,and the third needle may include a biocompatible conductive needle witha diameter between about 100 μm and about 200 μm, and a length betweenabout 0.1 cm and about 1 cm. In one embodiment, each of the firstneedle, the second needle, and the third needle may include abiocompatible metallic needle, for example, a steel needle. In oneexample, each of the first needle, the second needle, and the thirdneedle may include an acupuncture needle.

In an exemplary embodiment, each of the first needle, the second needle,and the third needle may comprise a biocompatible conductive needle witha sensing tip. The sensing tip may have a diameter between about 100 μmand about 200 μm, and a length between about 0.1 cm and about 1 cm. Inan exemplary embodiment, a layer (an array) of CNTs, for example,VAMWCNTs may be coated on each sensing tip of the first needle, thesecond needle, and the third needle.

FIG. 1J shows a schematic view of exemplary working electrode 158,consistent with one or more exemplary embodiments of the presentdisclosure. Each of the exemplary counter electrode 160 and exemplaryreference electrode 162 may be similar to exemplary working electrode158 shown in FIG. 1J. Exemplary working electrode 158 may includeexemplary first needle 180 with sensing tip 182. In an exemplaryembodiment, sensing tip 182 may be coated with an array of VAMWCNTs 184.

In an exemplary embodiment, a catalyst layer may be deposited on sensingtip 182. The catalyst layer may include a layer of Nickel (Ni) with athickness of less than about 10 nm that may be coated on sensing tip 182by an E-beam evaporation system at a temperature of about 120° C. with adepositing rate of about 0.1 Angstroms/s. Exemplary array of VAMWCNTs184 may be grown on the catalyst layer using a direct current plasmaenhanced chemical vapor deposition (DC-PECVD) system as described hereinabove.

Referring again to FIG. 1A, in an exemplary embodiment, electrochemicalstimulator-analyzer 104 may include a potentiostat circuit. An exemplarypotentiostat circuit may be configured to measure electrochemicalresponses from working electrode 108 by applying a periodic input signalto reference electrode 112 and measuring an electric current flowingfrom counter electrode 110 to working electrode 108. In an exemplaryembodiment, an electric voltage at working electrode 108 may beamplified by a series of low noise amplifiers (LNAs) to measure arespective electrochemical response. Different electrochemical responsesmay be obtained for different frequencies by varying a frequency of theinput signal. However, an output signal of the potentiostat circuit maytend to overshoot at high frequencies, leading to instability ofmeasurements. In an exemplary embodiment, to prevent an excessiveincrease of the output signal, the output signal amplitude may becompared with a reference value utilizing a comparator circuit, and anoutput of the comparator circuit may be utilized to adjust an inputsignal amplitude so that the output signal may not exceed the referencevalue. In an exemplary embodiment, current buffer amplifiers (CBAs) andcompensators may also utilized in the potentiostat circuit to furtherstabilize the output signal by lowering the impact of input signalvariations on the output signal amplitude.

FIG. 1K shows a schematic of a first implementation of a potentiostatcircuit, consistent with one or more exemplary embodiments of thepresent disclosure. In an exemplary embodiment, electrochemicalstimulator-analyzer 104 may include a potentiostat circuit 104A. In anexemplary embodiment, potentiostat circuit 104A may include a controlamplifier 10402, a transimpedance amplifier 10404, a peak detectorcircuit 10406, a feedback network 10408, a periodic wave generator10410, and a comparator circuit 10412.

In an exemplary embodiment, control amplifier 10402 may include a firstcontrol input 10414, a second control input 10416 that may be coupled toreference electrode 112, and a control output 10418 that may be coupledto counter electrode 110. In an exemplary embodiment, control amplifier10402 may be configured to generate a control voltage at control output10418 by amplifying a voltage difference between first control input10414 and second control input 10416. In an exemplary embodiment,control amplifier 10402 may include a differential amplifier. Anexemplary differential amplifier may include a first input node that maybe connected to first control input 10414 and a second input nodeconnected to second control input 10416. Therefore, an exemplarydifferential amplifier may obtain the voltage difference between firstcontrol input 10414 and second control input 10416 by measuring avoltage difference between the first input node and the second inputnode. In an exemplary embodiment, the voltage difference may thenmultiplied by a gain of the differential amplifier to generate thecontrol voltage at control output 10418. In exemplary embodiment,control amplifier 10402 may include an operational amplifier (op-amp).As a result, in exemplary embodiment, an electric potential at firstcontrol input 10414 may be transmitted to reference electrode 112through second control input 10416 (since electric potentials at op-ampinputs may be approximately equal). Therefore, in exemplary embodiment,a voltage at reference electrode 112 may be adjusted by adjusting avoltage of first control input 10414. In an exemplary embodiment,periodic wave generator 10410 may be utilized to adjust the voltage offirst control input 10414, as described below. In exemplary embodiment,exciting reference electrode 112 with an electric potential may cause aflow of an electric current from working electrode 108 to control output10418 through counter electrode 110.

In exemplary embodiment, transimpedance amplifier 10404 may include atransimpedance output 10420 and a transimpedance input 10422. In anexemplary embodiment, transimpedance input 10422 may be connected toworking electrode 108. In an exemplary embodiment, transimpedanceamplifier 10404 may be configured to generate a transimpedance voltageat transimpedance output 10420 by amplifying a voltage of transimpedanceinput 10422. In an exemplary embodiment, the voltage of transimpedanceinput 10422 may be multiplied by a gain of the transimpedance amplifierto generate an amplified voltage at transimpedance output 10420. Inexemplary embodiment, transimpedance amplifier 10404 may include anop-amp. In exemplary embodiment, transimpedance input 10422 may beconnected to a negative input of an exemplary op-amp, whereas a positiveinput of an exemplary op-amp may be connected to ground (negative andpositive inputs are not shown in FIG. 1K). As a result, in exemplaryembodiment, an electric current flowing through working electrode 108may be converted to a respective voltage at transimpedance output 10420by passing through feedback network 10408 (since an amount of electriccurrent that may pass through transimpedance input 10422 to an exemplarynegative op-amp input may be insignificant). In other words, inexemplary embodiment, the electric current at working electrode 108 maybe measured by recording a respective voltage at transimpedance output10420).

In an exemplary embodiment, peak detector circuit 10406 may include adetector output 10424 and a detector input 10426. In an exemplaryembodiment, detector input 10426 may be coupled to transimpedance output10420. In an exemplary embodiment, peak detector circuit 10406 may beconfigured to detect a maximum voltage at detector input 10426 in agiven period of time and transmit the maximum voltage to detector output10420. In an exemplary embodiment, peak detector circuit 10406 mayinclude a capacitor which may be charged by through detector input10426. In an exemplary embodiment, peak detector circuit 10406 mayfurther include a diode which may be forward biased when the voltage ofdetector input 10426 exceeds a voltage of the capacitor and may bereverse biased when the voltage of detector input 10426 becomes lowerthan the capacitor voltage, causing the capacitor to be disconnectedfrom detector input 10426. As a result, the maximum voltage at detectorinput 10426 may be stored by an exemplary capacitor as long as thecapacitor is not reset. In an exemplary embodiment, the capacitor may beconnected to detector output 10420. Therefore, in an exemplaryembodiment, detector output 10420 may hold the maximum voltage until ahigher voltage is detected at detector input 10426 by peak detectorcircuit 10406. As a result, in an exemplary embodiment, peak values ofelectric signals at working electrode 108 (which may be transmitted todetector input 10426 through transimpedance amplifier 10404) may bedetected by peak detector circuit 10406. In an exemplary embodiment,detected peak values of signals at working electrode 108 may be utilizedto improve stability of potentiostat circuit 104A. In an exemplaryembodiment, peak detector circuit 10406 may be configured to store themaximum voltage until the given period of time passes. In an exemplaryembodiment, the given period of time may be determined based on aduration in which an electrochemical response may be recorded. Forexample, the given period of time may be set to an expected duration inwhich an exemplary CV diagram is recorded. In an exemplary embodiment,the maximum voltage may be stored in an exemplary capacitor for thegiven period of time. In an exemplary embodiment, peak detector circuit10406 may be reset by discharging the capacitor after the given periodof time passes.

In an exemplary embodiment, periodic wave generator 10410 may beconfigured to generate a periodic wave at first control input 10414responsive to periodic wave generator 10410 becoming active In anexemplary embodiment, comparator circuit 10412 may be utilized toactivate periodic wave generator 10410, as described below. Whenperiodic wave generator 10410 is active, an exemplary periodic wave maybe transmitted to counter electrode 110 through second control input10416 to reference electrode 112. In an exemplary embodiment, periodicwave generator 10410 may be configured to adjust the voltage of firstcontrol input 10414 by generating a periodic sawtooth wave at firstcontrol input 10414, as described below. As a result, in an exemplaryembodiment, counter electrode 110 may be excited with a sawtooth wave,which may facilitate recording CV diagrams from respectiveelectrochemical responses due to moderately slow sweep rates of sawtoothwaves. In an exemplary embodiment, periodic wave generator 10410 may befurther configured to couple first control input 10414 to groundresponsive to periodic wave generator 10410 becoming inactive. In anexemplary embodiment, comparator circuit 10412 may be utilized todeactivate periodic wave generator 10410, as described below.

FIG. 1L shows a schematic of a periodic wave generator, consistent withone or more exemplary embodiments of the present disclosure. In anexemplary embodiment, periodic wave generator 10410 may include a pulsewave generator 10452, an op-amp 10454 that may be coupled to pulse wavegenerator 10452, an RC circuit 10456, and a field effect transistor(FET) M₁.

In an exemplary embodiment, pulse wave generator 10452 may be configuredto generate a periodic rectangular wave. In an exemplary embodiment,either an analog or a digital pulse generator may be utilized toimplement pulse wave generator 10452. In an exemplary embodiment, a dutycycle of rectangular pulses in the periodic rectangular wave may be setto 50% to generate square pulses.

In an exemplary embodiment, op-amp 10454 may include a positive input10458, a negative input 10460, and an op-amp output 10462. In anexemplary embodiment, positive input 10458 may be connected to ground,negative input 10460 may be coupled to an output of pulse wave generator10452, and op-amp output 10462 may be connected to first control input10414. In an exemplary embodiment, RC circuit 10456 may be connectedbetween op-amp output 10462 and negative input 10460, and may include afirst resistor R₁ and a first capacitor C₁ that may be connected inparallel.

In an exemplary embodiment, periodic wave generator 10410 may furtherinclude a second resistor R₂ and a third resistor R₃. In an exemplaryembodiment, second resistor R₂ may be connected to negative input 10460and third resistor R₁ may be connected between second resistor R₂ andthe output of pulse wave generator 10452. As a result, in an exemplaryembodiment, an output current of pulse wave generator 10452 flowingthrough second resistor R₂ and third resistor R₃ may be transmitted toop-amp output 10462 through RC circuit 10456 (since an amount ofelectric current that may pass into op-amp 10454 through an exemplarynegative input 10460 may be insignificant). Therefore, in an exemplaryembodiment, the transmitted current to op-amp output 10462 may preservea shape and frequency of the output current of pulse wave generator10452. However, a voltage shape at op-amp output 10462 may be determinedbased on values of first resistor R₁ and first capacitor C₁ in RCcircuit 10456. In an exemplary embodiment, different values of firstresistor R₁ and first capacitor C may result in differentcharge/discharge time for capacitor C₁, resulting in different voltageshapes at op-amp output 10462. For example, the voltage at op-amp output10462 may be shaped as a sawtooth wave if the values of first resistorR₁ and first capacitor C₁ satisfy a set of exemplary conditions, asdescribed below.

In an exemplary embodiment, first resistor R₁, first capacitor C₁,second resistor R₂, and third resistor R₃ may satisfy a set ofconditions defined by the following:R ₁ C ₁>100/f _(pw)R ₂ =R ₃<0.1R ₁

where f_(pw) is a frequency of the periodic rectangular wave. In anexemplary embodiment, the above set of conditions may ensure that thetime constant of RC circuit 10456 (i.e., R₁C₁) may be significantlyhigher than 10T_(pw) where T_(pw) is a period of the periodicrectangular wave, and each of second resistor R₂ and third resistor R₃may be negligible compared to first resistor R₁. As a result, in anexemplary embodiment, the periodic rectangular wave may be converted toa sawtooth wave at op-amp output 10462.

In an exemplary embodiment, FET M₁ may include a source 10460, a drain10466, and a gate 10468. In an exemplary embodiment, source 10460 may beconnected to ground. In an exemplary embodiment, drain 10466 may beconnected between second resistor R₂ and third resistor R₃, and gate10468 may be connected to an activation input 10427. In an exemplaryembodiment, FET M₁ may be turned off by applying a deactivation voltageto gate 10468, for example, by connecting activation input 10427 toground. As a result, in an exemplary embodiment, op-amp 10454 may becoupled to third resistor R₃ through second resistor R₂ and therefore,an output voltage of pulse wave generator 10452 may be transmitted toop-amp output 10462. On the other hand, in an exemplary embodiment, FETM₁ may be turned on by applying an activation voltage (for example, anegative voltage for an n-channel FET or a negative voltage for ap-channel FET) to activation input 10427. As a result, in an exemplaryembodiment, second resistor R₂ may be coupled to ground through FET M₁and consequently, a voltage at op-amp output 10462 may be reduced asfirst capacitor C₁ is being discharged.

Referring again to FIG. 1K, in an exemplary embodiment, comparatorcircuit 10412 may be configured to activate periodic wave generator10410 by providing the activation voltage to activation input 10427 ofperiodic wave generator 10410 responsive to a voltage of detector output10420 being smaller than a reference voltage 10428. In an exemplaryembodiment, comparator circuit 10412 may be further configured todeactivate periodic wave generator 10410 by providing the deactivationvoltage to activation input 10427 responsive to a voltage of detectoroutput 10420 being equal to or larger than reference voltage 10428. Asdiscussed earlier, since peak values of electric signals at workingelectrode 108 may be detected by detector circuit 10406, utilizingcomparator circuit 10412 may prevent an excessive increase in amplitudesof electric signals at working electrode 108 by deactivating periodicwave generator 10410 which may stop an excitation of reference electrode112. As a result, in an exemplary embodiment, a flow electric currentthrough working electrode 108 may be reduced.

In an exemplary embodiment, comparator circuit 10412 may include a firstcomparator input 10446, a second comparator input 10448, and acomparator output 10450. In an exemplary embodiment, first comparatorinput 10446 may be connected to detector output 10420 and comparatoroutput 10450 may be connected to activation input 10427.

In an exemplary embodiment, second comparator input 10448 may includereference voltage 10428. An exemplary second comparator input 10448 maybe coupled to a DC voltage supply that may include a DC voltage. In anexemplary embodiment, second comparator input 10448 may be coupled tothe DC voltage supply via a variable resistor. An exemplary variableresistor may be implemented utilizing a potentiometer or a rheostat. Anexemplary variable resistor may be configured to provide referencevoltage 10428 to second comparator input 10448 by transmitting afraction of the DC voltage to second comparator input 10448. In anexemplary embodiment, the fraction of the DC voltage may be determinedby varying a resistivity of the variable resistor until referencevoltage 10428 is obtained.

In an exemplary embodiment, comparator circuit 10412 may be configuredto provide the activation voltage to comparator output 10450 responsiveto a voltage of first comparator input 10446 being smaller than avoltage of second comparator input 10448. In an exemplary embodiment,comparator circuit 10412 may be further configured to provide thedeactivation voltage to comparator output 10450 responsive to thevoltage of first comparator input 10446 being equal to or larger thanthe voltage of second comparator input 10448. In an exemplaryembodiment, an analog comparator may be utilized to implement comparatorcircuit 10412. In an exemplary embodiment, the analog comparator may beconfigured to generate each of the activation voltage and thedeactivation voltage at an output node of the analog comparator. Anexemplary output node of the analog comparator may be connected tocomparator output 10450 to provide each of the activation voltage andthe deactivation voltage to comparator output 10450.

In an exemplary embodiment, feedback network 10408 may be connectedbetween detector input 10426 and transimpedance input 10422. In anexemplary embodiment, feedback network 10408 may include a feedbackresistor. In an exemplary embodiment, a resistance R_(f) of the feedbackresistor may be equal to

$\frac{V_{ref}}{I_{\max}},$where V_(ref) is a magnitude of reference voltage

and I_(max) is an upper limit of an electric current flowing throughdetector input 10426. As a result, in an exemplary embodiment, anelectric voltage at detector input 10426 may not exceed V_(ref) as longas the electric current flowing through detector input 10426 remainslower than I_(max). In an exemplary embodiment, upper limit I_(max) maybe determined based on an expected maximum value of an electric currentthat flows through working electrode 108 (which may also flow throughfeedback network 10408, as discussed earlier). Therefore, in anexemplary embodiment, determination of resistance R_(f) based on I_(max)may further stabilize potentiostat circuit 104A by preventing measuredelectric potentials from reaching reference voltage 10428.

In an exemplary embodiment, potentiostat circuit 104A may furtherinclude a unity gain amplifier 10430 that may be connected betweenreference electrode 112 and second control input 10416. In an exemplaryembodiment, unity gain amplifier 10430 may include a first unity gaininput 10432, a unity gain output 10434, and a second unity gain input10436. In an exemplary embodiment, first unity gain input 10432 may beconnected to reference electrode 112, unity gain output 10434 may beconnected to second control input 10416, and second unity gain input10436 may be connected to unity gain output 10434 and therefore, tosecond control input 10416. In an exemplary embodiment, unity gainamplifier 10430 may be configured to transmit a voltage at referenceelectrode 112 to unity gain output 10434 by amplifying a voltagedifference between first unity gain input 10432 and second unity gaininput 10436. In exemplary embodiment, unity gain amplifier 10430 mayinclude a differential amplifier. An exemplary differential amplifiermay include an exemplary first input node that may be connected to firstunity gain input 10432 and an exemplary second input node connected tosecond unity gain input 10436. Therefore, an exemplary differentialamplifier may obtain the voltage difference between first unity gaininput 10432 and second unity gain input 10436 by measuring a voltagedifference between the exemplary first input node and the exemplarysecond input node. In an exemplary embodiment, the voltage differencemay then be multiplied by a gain of the differential amplifier togenerate an amplified voltage at unity gain output 10434. In exemplaryembodiment, unity gain amplifier 10430 may include an op-amp. Therefore,in an exemplary embodiment, the voltage of first control input 10414(i.e., an output voltage of periodic wave generator 10410) may beprovided to reference electrode 112 through second unity gain input10436 that is connected to second control input 10416, because electricpotentials of first unity gain input 10432 and second unity gain input10436 may be almost equal.

FIG. 1M shows a schematic of a second implementation of a potentiostatcircuit, consistent with one or more exemplary embodiments of thepresent disclosure. In an exemplary embodiment, electrochemicalstimulator-analyzer 104 may include a potentiostat circuit 104B. In anexemplary embodiment, potentiostat circuit 104B may include potentiostatcircuit 104A and some additional elements. Exemplary additional elementsmay include current buffer amplifiers and analog compensators, which mayimprove stability of electrochemical stimulator-analyzer 104 at highersignal amplitudes and frequencies, thereby extending a range offrequency and/or amplitude in which electrochemical stimulator-analyzer104 may operate. In an exemplary embodiment, potentiostat circuit 104Bmay further include a first current buffer amplifier (CBA) 10438 thatmay be connected between control amplifier 10402 and counter electrode110. In an exemplary embodiment, first CBA 10438 may be configured totransfer an electric current flowing through control output 10418 tocounter electrode 110.

In an exemplary embodiment, potentiostat circuit 104B may furtherinclude a second CBA 10440 that may be connected between transimpedanceamplifier 10404 and peak detector circuit 10406. In an exemplaryembodiment, second CBA 10440 may be configured to transfer an electriccurrent flowing through transimpedance output 10420 to detector input10426.

In an exemplary embodiment, potentiostat circuit 104B may furtherinclude a first analog compensator 10442 that may be connected betweencounter electrode 110 and first control input 10414. In an exemplaryembodiment, first analog compensator 10442 may be configured tocompensate voltage variations at counter electrode 110 responsive tovoltage variations at first control input 10414. In an exemplaryembodiment, first analog compensator 10442 may include a firstcompensation capacitor. In an exemplary embodiment, potentiostat circuit104B may further include a second analog compensator 10444 that may beconnected to second control input 10416. In an exemplary embodiment,second analog compensator 10444 may be configured to compensate voltagevariations at second control input 10416. In an exemplary embodiment,second analog compensator 10444 may include a second compensationcapacitor and a compensation resistor that may be connected in series.In an exemplary embodiment, values of the first compensation capacitor,the second compensation capacitor, and the compensation resistor may beset to about 22 pF, 47 pF, and 4.99 kΩ, respectively. As a result, in anexemplary embodiment, a scan rate of about 1 V/μs may obtained at afrequency of about f_(pw)=1 MHz for recording electrochemical responsesutilizing potentiostat circuit 104B, which may be suitable for highspeed applications.

In another aspect of the present disclosure, a method for cancerdiagnosis is disclosed. FIG. 2A shows an exemplary implementation ofmethod 200 for cancer diagnosis, consistent with one or more exemplaryembodiments of the present disclosure. Method 200 may include putting anarray of vertically aligned multi-walled carbon nanotubes (VAMWCNTs) ofa sensor in contact with a suspicious sample (step 202), recording anelectrochemical response from the suspicious sample, where theelectrochemical response may include an oxidation current peak (step204), and detecting a cancerous state in the suspicious sampleresponsive to a larger amount of the oxidation current peak than athreshold value (step 206). The sensor may be similar to exemplarysensor 102 described hereinabove.

Step 202 may include putting the array of vertically alignedmulti-walled carbon nanotubes (VAMWCNTs) of the sensor in contact withthe suspicious sample. In an exemplary implementation, putting the arrayof VAMWCNTs of the sensor in contact with the suspicious sample mayinclude one of dropping the suspicious sample onto the sensor, placingthe suspicious sample onto the sensor, squeezing the sensor into thesuspicious sample, inserting the sensor into the suspicious sample, andcombinations thereof.

In an exemplary embodiment, the suspicious sample may include one of aliquid suspicious sample, a solid suspicious sample, and combinationsthereof. In an exemplary embodiment, the suspicious sample may includeone of a plurality of cell lines, a biopsied sample from a human oranimal body, a removed sample from a human or animal body by surgery, aportion of a living tissue in a human or animal body, and a portion of aliving tissue in a human or animal body during surgery.

In an exemplary implementation, the sensor may be similar to sensor 102and may include a substrate, a catalyst layer, and three arrays ofvertically aligned multi-walled carbon nanotubes (VAMWCNTs) grown on thecatalyst layer. Three arrays of VAMWCNTs may include a working electrodethat may include a first array of VAMWCNTs, a reference electrode thatmay include a second array of VAMWCNTs, and a counter electrode that mayinclude a third array of VAMWCNTs. In an exemplary implementation, thesensor may further include a passivation layer between the substrate andthe catalyst layer.

In an exemplary implementation, the sensor may include one of a CNTbased electrochemical chip similar to exemplary CNT basedelectrochemical chip 102 shown in FIG. 1B, and a cancer diagnosis probe(CDP) similar to exemplary CDP 102 shown in FIG. 1E. The substrate ofthe cancer CDP may include three needles, where each needle of the threeneedles may be coated by an array of VAMWCNTs of the three arrays ofVAMWCNTs. In an exemplary implementation, the sensor may includeexemplary sensor 102 as shown schematically in FIGS. 1A, 1B, and 1E.

FIG. 2B shows a schematic implementation of step 202 that may includeputting the array of vertically aligned multi-walled carbon nanotubes(VAMWCNTs) grown on tip of each needle electrode of three needleselectrodes 132, 134, and 138 of exemplary cancer diagnosis probe (CDP)102 in contact with exemplary suspicious sample 250, consistent with oneor more exemplary embodiments of the present disclosure. Step 102 mayinclude inserting or squeezing exemplary cancer diagnosis probe (CDP)102 in exemplary suspicious sample 250.

In an exemplary implementation, putting the array of VAMWCNTs ofexemplary sensor 102 in contact with the suspicious sample may takeplace temporarily or over a time duration of less than 1 seconds for areal-time cancer diagnosis case. In an exemplary embodiment, putting thearray of VAMWCNTs of exemplary sensor 102 in contact with the suspicioussample may take place temporarily or over a time duration of less than 1seconds for in vivo or in vitro cancer diagnosis using exemplary sensorwhich may be an exemplary CDP or exemplary CNT based electrochemicalchip. In an exemplary embodiment, putting the array of VAMWCNTs ofexemplary sensor 102 in contact with the suspicious sample may be for atime duration of about 12 hours or more for in vitro cancer diagnosiscases with high levels of accuracy utilizing exemplary CNT basedelectrochemical chip 102. In an exemplary embodiment, putting the arrayof VAMWCNTs of exemplary sensor 102 in contact with the suspicioussample may be carried out in a time duration of about 0.1 seconds toabout 24 hours.

Step 204 may include recording the electrochemical response from thesuspicious sample, where the electrochemical response may include anoxidation current peak. In an exemplary embodiment, the electrochemicalresponse may include a cyclic voltammetry (CV) diagram of hypoxicglycolysis chemical reaction in biological cells within the suspicioussample. In an exemplary embodiment, the electrochemical response mayinclude a cyclic voltammetry (CV) diagram of H₂O₂ relatedoxidation/reduction chemical reaction in biological cells within thesuspicious sample. The concentration of H₂O₂ may be in correlation withthe hypoxia glycolysis occurred in tumor cells. In an exemplaryembodiment, the electrochemical response may include a cyclicvoltammetry (CV) diagram of H₂O₂ oxidation that may be electricallysensed by VAMWCNTs in biological cells within the suspicious sample. Inan exemplary embodiment, the electrochemical response may include anoxidation current peak of exemplary CV diagram of hypoxic glycolysischemical reaction in biological cells within a suspicious sample.

In an exemplary implementation, recording the electrochemical responsefrom the suspicious sample (step 204) may include connecting the sensorto an electrochemical stimulator-analyzer, applying an electricalvoltage on the sensor using the electrochemical stimulator-analyzer, andmeasuring the electrochemical response from the suspicious sample usingthe electrochemical stimulator-analyzer. In an exemplary embodiment, theelectrochemical stimulator-analyzer may include a potentiostat.

Step 206 may include detecting the cancerous state in the suspicioussample responsive to a larger amount of the oxidation current peak thana threshold value. In an exemplary embodiment, the threshold value mayinclude an oxidation current peak of about 700 μA or more when a timeduration of putting the array of vertically aligned multi-walled carbonnanotubes (VAMWCNTs) of the sensor in contact with the suspicious sample(step 202) may be more than about 12 hours. In an exemplary embodiment,the threshold value may include an oxidation current peak of about 80 μAor more when a time duration of putting the array of vertically alignedmulti-walled carbon nanotubes (VAMWCNTs) of the sensor in contact withthe suspicious sample (step 202) may be about 5 seconds or less.

FIG. 2C shows an implementation of detecting the cancerous state in thesuspicious sample (step 206), consistent with one or more exemplaryembodiments of the present disclosure. Detecting the cancerous state inthe suspicious sample (step 206) may include recording a referenceelectrochemical response from a reference solution, where the referenceelectrochemical response may include a reference oxidation current peak(step 208), comparing the electrochemical response with the referenceelectrochemical response (step 210), and detecting the cancerous statein the suspicious sample responsive to a larger oxidation current peakof the electrochemical response in comparison with the referenceoxidation current peak (step 212). In an exemplary embodiment, thereference solution may include a lactate solution with a lactateconcentration of about 0.05 mM or more.

Disclosed systems, methods and sensors herein may have variousimplementations, all based on measuring H₂O₂ oxidation current peak dueto hypoxia glycolysis and reverse Warburg phenomena in cancer cells inorder to for diagnosing cancerous tumors in real-time and with highlyaccuracy. Exemplary CDP 102 may be utilized via exemplary system 100and/or utilizing exemplary method 200 for non-invasively diagnosing, inreal-time, a presence of pre-neoplastic/neoplastic cells in eitherinternal or external margins of a patient during tumor surgery, forexample, breast cancer surgery. The exemplary systems, methods, andsensors may be capable of instantaneously determining an amount of H₂O₂released from cancer or atypical cells, through reverse Warburg effectand hypoxia assisted glycolysis pathways, in a quantitativeelectrochemical manner. Reverse Warburg effect and hypoxia assistedglycolysis pathways may lead to high levels of H₂O₂ concentration incancerous tumors in comparison with healthy tissues. Due to limitedprecision of conventional H&E pathology of biopsy samples andrequirement to time-consuming preparation and consideration of manyblocks and slides for complete evaluation of biopsy samples, exemplarysystems, methods, and sensors of the present disclosure may be appliedfor cancer diagnosis, which may be based on live detecting the hypoxiaglycolytic functions of high risk/premalignant cells based on the H₂O₂released from cancer or atypical cells (through reverse Warburg effect10 and hypoxia assisted glycolysis pathways). The exemplary systems,methods, and sensors may be utilized for diagnosing all canceroustumors, in which hypoxia glycolysis may be the main differentialmechanism between the phenotypes of healthy, precancerous and cancerouscells.

In an exemplary implementation, method 200 may further includefabrication of exemplary sensor 102 (not illustrated), for example,exemplary CDP 102. In an exemplary implementation, method 200 may beutilized for in-vivo cancer diagnosis within a living tissue utilizingexemplary CDP 102.

FIG. 2E shows an exemplary implementation of exemplary method 220 forin-vivo cancer diagnosis within a living tissue, consistent with one ormore exemplary embodiments of the present disclosure. Exemplary method220 may be similar to method 200 shown in FIG. 2A. Exemplary method 220may include preparing an electrochemical probe by fabricating threeintegrated electrodes (step 221), putting tips of the three integratedelectrodes in contact with a portion of the living tissue by insertingthe tips of the three integrated electrodes into the portion of theliving tissue (step 222), recording an electrochemical response from theportion of the living tissue, where the electrochemical response mayinclude a cyclic voltammetry (CV) diagram with an oxidation current peakof hypoxic glycolysis chemical reaction in biological cells within theportion of the living tissue (step 224), and detecting acancer-involving status of the portion of the living tissue based on theoxidation current peak (step 226).

In detail, step 221 may include preparing an electrochemical probe. Inan exemplary embodiment, the electrochemical probe may be similar toexemplary CDP 102 that is shown in FIGS. 1E, 1H and 1I. FIG. 2F shows anexemplary implementation of preparing an exemplary electrochemical probesimilar to CDP 102 (step 221), consistent with one or more exemplaryembodiments of the present disclosure. Step 221 may include fabricatingthree integrated electrodes by coating a layer of vertically alignedmulti-walled carbon nanotubes (VAMWCNTs) on tips of three electricallyconductive biocompatible needles (step 230), and fixing the threeintegrated electrodes at one end of a handle (or a holding member) (step232).

FIG. 2G shows an exemplary implementation of fabricating threeintegrated electrodes by coating a layer of vertically alignedmulti-walled carbon nanotubes (VAMWCNTs) on tips of three electricallyconductive biocompatible needles (step 230), consistent with one or moreexemplary embodiments of the present disclosure. Step 230 may includedepositing a catalyst layer on the tips of the three electricallyconductive biocompatible needles (step 240), and growing an array ofVAMWCNTs on the deposited catalyst layer (step 242). In an exemplaryimplementation, step 230 may include fabricating three integratedelectrodes by coating three respective layers of VAMWCNTs on tips ofthree electrically conductive biocompatible needles.

In detail, step 240 may include depositing a catalyst layer on tips ofthree electrically conductive biocompatible needles. In an exemplaryimplementation, step 240 may include depositing three catalyst layers onthree respective tips of the three electrically conductive biocompatibleneedles. In an exemplary implementation, step 240 may include depositinga respective layer of Nickel (Ni) with a thickness of less than about 10nm using an E-beam evaporation system at a temperature of about 120° C.with a depositing rate of about 0.1 Angstroms/s on each tip of the tipsof the three electrically conductive biocompatible needles.

Furthermore, step 242 may include growing an array of VAMWCNTs on thedeposited catalyst layer on each tip of the tips of the threeelectrically conductive biocompatible needles. FIG. 2H shows anexemplary implementation of growing an array of VAMWCNTs on thedeposited catalyst layer (step 242), consistent with one or moreexemplary embodiments of the present disclosure. Step 242 may includeannealing the deposited catalyst layer at a temperature of about 680° C.in an H₂ environment with a flow rate of about 20 standard cubiccentimeters per minute (sccm) to 35 sccm for about 30 minutes (step244), graining the annealed catalyst layer by plasma hydrogenation ofsurface of the catalyst layer for about 5 minutes with an intensity ofabout 5.5 W·cm⁻² (step 246), and growing VAMWCNTs on the grainedcatalyst layer in a chamber by introducing a plasma comprising a mixtureof C₂H₂ with flow rate of about 5 sccm and H₂ with flow rate of about 35sccm to the chamber for about 15 minutes (step 248). In an exemplaryimplementation, graining the annealed catalyst layer by plasmahydrogenation of surface of the catalyst layer for about 5 minutes withan intensity of about 5.5 W·cm⁻¹ (step 246) may result in catalystgraining, and formation of nano-sized islands of the catalyst.

Referring to FIG. 2E, step 222 may include putting tips of the threeintegrated electrodes in contact with a portion of the living tissue byinserting the tips of the three integrated electrodes into the portionof the living tissue. In an exemplary implementation, step 222 mayinclude putting tips of exemplary three integrated electrodes ofexemplary CDP 102 in contact with a portion of a living tissue byinserting the tips of the three integrated electrodes into the portionof the living tissue. As used herein, “the portion of the living tissue”may refer to an implementation of “the suspicious sample” describedhereinabove, which may include a biological sample that may besuspicious to be cancerous. FIG. 2C shows a schematic view of anotherexemplary implementation of putting electrodes 158, 160, and 162 ofexemplary CDP 102 in contact with exemplary portion 262 of living tissue260 (step 222), consistent with one or more exemplary embodiments of thepresent disclosure. Putting electrodes 158, 160, and 162 of exemplaryCDP 102 in contact with exemplary portion 262 of living tissue 260 mayinclude inserting sensing part 154 into exemplary portion 262 of livingtissue 260.

In an exemplary implementation, putting electrodes 158, 160, and 162 ofexemplary CDP 102 in contact with exemplary portion 262 of living tissue260 may include at least one of putting electrodes 158, 160, and 162inside portion 262 of living tissue 260, inserting electrodes 158, 160,and 162 inside portion 262 of living tissue 260, interacting a secretionof living tissue 260 with electrodes 158, 160, and 162, squeezingelectrodes 158, 160, and 162 inside portion 262 of living tissue 260,and combinations thereof. In an exemplary embodiment, insertingelectrodes 158, 160, and 162 inside portion 262 of living tissue 260 mayinclude penetrating electrodes 158, 160, and 162 into portion 262 ofliving tissue 260. In one implementation, putting electrodes 158, 160,and 162 of exemplary CDP 102 in contact with portion 262 of livingtissue 260 (step 222) may be done during at least one of a surgeryoperation, a mastectomy operation, a biopsy operation, an endomicroscopyoperation, an optical biopsy operation, a clinical examination of apatient, and combinations thereof. In one implementation, puttingelectrodes 158, 160, and 162 of exemplary CDP 102 in contact withexemplary portion 262 of living tissue 260 may include insertingelectrodes 158, 160, and 162 of exemplary CDP 102 in portion 262 ofliving tissue 260 with an insertion depth between about 3 mm and about 5mm.

In an exemplary embodiment, portion 262 of living tissue 260 may be inliquid form or solid form. In further detail, in an exemplaryembodiment, portion 262 may comprise at least one of a liquid samplesuspicious to be cancerous, a solid sample suspicious to be cancerous,and combinations thereof.

In an exemplary embodiment, portion 262 of living tissue 260 may includeat least one of a biopsied sample from a human or animal body, a sampleresected from a human or animal body by surgery, a portion of livingtissue 260 in a human or animal body near to skin, an exemplary portion262 of living tissue 260 of a human or animal body that may beaccessible during surgery (tumor removal surgery) or biopsy operation, asuspicious mass to be cancerous in a human or animal body, a removedsample from a human or animal body by surgery, and combinations thereof.

Moreover, step 224 may include recording an electrochemical responsefrom the portion of the living tissue, where the electrochemicalresponse may include a cyclic voltammetry (CV) diagram with an oxidationcurrent peak of hypoxic glycolysis chemical reaction in biological cellswithin the portion of the living tissue. In an exemplary implementation,step 224 may include recording a CV diagram with an oxidation currentpeak of hypoxic glycolysis chemical reaction from portion 262 of livingtissue 260 utilizing exemplary CDP 102. In an exemplary implementation,recording the electrochemical response from the suspicious sample (step224) may include recording the electrochemical response from exemplarysuspicious sample 250 (FIG. 2B) or exemplary portion 262 of livingtissue 260 (FIG. 2C). In an exemplary embodiment, the electrochemicalresponse may be recorded using exemplary CDP 102 that is shown in FIGS.1E, 1H and 1I. In an exemplary embodiment, the electrochemical responsemay include a cyclic voltammetry (CV) diagram with an oxidation currentpeak of hypoxic glycolysis chemical reaction in biological cells withinexemplary portion 262 of the living tissue 260.

In an exemplary implementation, recording the electrochemical responsefrom exemplary portion 262 of living tissue 260 may include connectingexemplary CDP 102 to an electrochemical stimulator-analyzer, applying aset of electrical potentials to exemplary CDP 102 using theelectrochemical stimulator-analyzer, and recording a set of electricalcurrents respective to the applied set of electrical potentials fromexemplary portion 262 of the living tissue 260 using the exemplary CDP102 and the electrochemical stimulator-analyzer. In an exemplaryembodiment, each of the measured set of electrical current may flow fromcounter electrode 110 to working electrode 108 when a respectiveelectrical potential of the set of electrical potentials is applied toCDP 102.

In an exemplary implementation, applying the set of electricalpotentials to exemplary CDP 102 may include applying a sweeping range ofelectrical potentials between about −1 V and about 1 V to exemplaryworking electrode 158 or exemplary working electrode 108. In anexemplary implementation, applying the set of electrical potentials toexemplary CDP 102 may include applying a sweeping range of electricalpotentials between about −0.8 V and about 0.8 V to exemplary workingelectrode 158 or exemplary working electrode 108. In an exemplaryembodiment, the electrochemical stimulator-analyzer may comprise apotentiostat.

In detail, step 226 may include detecting a cancer-involving status ofthe portion of the living tissue based on the oxidation current peak. Inan exemplary implementation, step 226 may include detecting acancer-involving status of exemplary suspicious sample 250 (FIG. 2B) orexemplary portion 262 of living tissue 260 (FIG. 2C). In an exemplaryimplementation, detecting the cancer-involving status of portion 262 ofliving tissue 260 based on the oxidation current peak (step 226) mayinclude detecting a healthy state at portion 262 of living tissue 260responsive to a value (an amount) of the oxidation current peak beingsmaller than a first threshold value, detecting a cancerous state atportion 262 of living tissue 260 responsive to the value of theoxidation current peak being larger than a second threshold value, anddetecting a moderately cancer-involved state at the portion 262 ofliving tissue 260 responsive to the value of the oxidation current peakbeing between the first threshold value and the second threshold value.

In an exemplary implementation, exemplary method 220 utilizing exemplaryCDP 102 may be utilized for in-vivo cancer diagnosis within all tissuesin a human or animal's body. In an exemplary implementation, exemplarymethod 220 utilizing exemplary CDP 102 may be utilized for in-vivocancer diagnosis of all cancerous tumors, in which hypoxia glycolysismay be the main differential mechanism between the phenotypes ofhealthy, precancerous and cancerous cells. In an exemplaryimplementation, detecting the cancer-involving status of portion 262 ofliving tissue 260 based on the oxidation current peak (step 226) mayinclude detecting presence of human breast cancer in a portion of abreast tissue responsive to the value of the oxidation current peakbeing equal to 203 μA or more, detecting the healthy state at theportion of the breast tissue responsive to the value of the oxidationcurrent peak being equal to 137 μA or less, and detecting a moderatelybreast cancer-involved state at the portion of the breast tissueresponsive to the value of the oxidation current peak being between 137μA and 203 μA.

In an exemplary implementation, detecting the cancer-involving status ofportion 262 of living tissue 260 based on the oxidation current peak(step 226) may include detecting presence of cervical cancer in aportion of a cervical tissue (cervix) responsive to the value of theoxidation current peak being equal to 145 μA or more, detecting thehealthy state at the portion of the cervical tissue (cervix) responsiveto the value of the oxidation current peak being equal to 115 μA orless, and detecting a moderately cervical cancer-involved state (or asuspicious-involved state) at the portion of the cervical tissue(cervix) responsive to the value of the oxidation current peak beingbetween 115 μA and 145 μA.

FIG. 2I shows an exemplary implementation of detecting thecancer-involving status of portion 262 of living tissue 260 based on theoxidation current peak (step 226), consistent with one or more exemplaryembodiments of the present disclosure. In detail, detecting thecancer-involving status of portion 262 of living tissue 260 based on theoxidation current peak (step 226) may include generating a set ofreference current peak values (step 270), looking up the oxidationcurrent peak within the generated set of reference current peak values(step 272), and detecting the cancer-involving status in portion 262 ofliving tissue 260 (step 274).

In detail, step 270 may include generating a set of reference currentpeak values. FIG. 2J shows an exemplary implementation of generating theset of reference current peak values (step 270), consistent with one ormore exemplary embodiments of the present disclosure. In an exemplaryimplementation, generating the set of reference current peak values(step 270) may include recording a set of CV diagrams from a pluralityof samples of living tissues using the electrochemical probe (i.e., CDP102)(step 280), measuring a set of reference current peaks respective tothe recorded set of CV diagrams for each sample of the plurality ofsamples of living tissues (step 282), determining status of each sampleby applying a pathological assay to each sample (step 284), andassigning the determined status of each sample to the respectivemeasured reference current peak (step 286). In an exemplaryimplementation, generating the set of reference current peak values(step 270) may include calibrating exemplary CDP 102 for an exemplaryliving tissue similar to living tissue 260. In such implementation, theplurality of samples of living tissues may include a plurality ofsamples of living tissues from the same organ, for example, breasttissue, of a plurality of human or animal bodies.

The determined status may include one of a healthy state, a cancerousstate, and a moderately cancer-involved state, based on result of theapplied pathological assay. In an exemplary implementation, detectingthe cancer-involving status in portion 262 of living tissue 260 (step274) may include detecting the healthy state for portion 262 of livingtissue 260 responsive to the oxidation current peak being in a firstrange of the generated set of reference current peak values assigned asbeing of the healthy state, detecting the cancerous state for portion262 of living tissue 260 responsive to the oxidation current peak beingin a second range of the generated set of reference current peak valuesassigned as being of the cancerous state, and detecting the moderatelycancer-involved state for portion 262 of living tissue 260 responsive tothe oxidation current peak being in a third range of the generated setof reference current peak values assigned as being of the moderatelycancer-involved state.

In an exemplary implementation, the whole process of exemplary method200 which may include, putting the array of VAMWCNTs of exemplary sensor102 in contact with the suspicious sample (step 202), recording theelectrochemical response from the suspicious sample (step 204), anddetecting the cancerous state in the suspicious sample (step 206) may becarried out in less than about 30 seconds. Similarly, in an exemplaryimplementation, steps 222-226 of exemplary method 220 which may includeputting electrodes 158, 160, and 162 of exemplary CDP 102 in contactwith exemplary portion 262 of living tissue 260 (step 222), recordingthe electrochemical response from exemplary portion 262 of living tissue260 (FIG. 2C) (step 224), and detecting the cancerous state in 262 ofliving tissue 260 (step 226) may be carried out in less than about 30seconds.

In an exemplary implementation, conducting cancer diagnosis process ofexemplary method 220 which may further include replacing a previouslyused sensing part 154 with a new sensing part 154 may take place in lessthan about 40 seconds. In an exemplary implementation, conducting cancerdiagnosis process of exemplary method 220 which may include replacing apreviously used sensing part 154 with a new sensing part 154, insertingexemplary CDP 102 including the new sensing part 154 into a targettissue by inserting new sensing part 154 into a target location withinthe target tissue, recording a CV response with a current peak from thetarget location, and detecting cancerous state of the target tissue maytake place in less than about 40 seconds. For example, replacing apreviously used sensing part 154 with a new sensing part 154, insertingexemplary CDP 102 including the new sensing part 154 into portion 262 ofliving tissue 260 by inserting new sensing part 154 into portion 262 ofliving tissue 260, recording a CV response with a current peak fromportion 262 of living tissue 260, and detecting cancerous state ofportion 262 of living tissue 260 may take place in less than about 40seconds.

In an exemplary implementation, replacing the previously used sensingpart 154 may include removing the previously used sensing part 154, andconnecting the new (fresh) sensing part 154 to handle 152. In anexemplary implementation, replacing the previously used sensing part 154may take a time interval of less than about 20 sec. In an exemplaryimplementation, recording the CV response with the current peak from atarget location (i.e., portion 262 of living tissue 260) may be carriedout in about 15 sec or less due to synchronized real-time processing.

Accordingly, in an exemplary embodiment, methods 200, and 220, provide aquick and efficient approach to instantaneously detect a tissue'scancerous state, including indicating presence of cancer. For example,exemplary CDP 102 may be utilized through exemplary methods 200, and 220for real-time high-accurate detecting cancer-involved margins in apatient's body. In such implementations, exemplary methods 200, and 220may be applied on at least one exemplary portion of a living tissue thatmay be suspicious to contain a cancerous tumor. In one implementation,exemplary methods 200, and 220 may be applied before a tumor removalsurgery, during a tumor removal surgery, after a tumor removal surgery,and combinations thereof. In an exemplary implementation, exemplary CDP102 may be utilized through exemplary methods 200, and 220 at suspiciousmargins around a dissected tumor after the tumor removal surgery todetermine whether the suspicious margins are cancerous or not.

In an exemplary implementation, electrochemical system 100 may beutilized for cancer diagnosis via exemplary method 200. FIG. 3A shows aschematic view of exemplary electrochemical reactions involved on sensor102 including exemplary VAMWCNTs 130 as shown in FIGS. 1D and 1G,consistent with one or more exemplary embodiments of the presentdisclosure. Presence of H₂O₂ active molecule released during hypoxiaglycolysis in a suspicious sample may be the main trigger of theelectrochemical reactions. Hence, the chemical reaction occurring on theworking electrode 108 including VAMWCNTs 130 may include:

$\begin{matrix}{{L - {Lactate} + O_{2}}\overset{\begin{matrix}{L - {Lactate}} \\{Oxidase}\end{matrix}}{\rightarrow}{{Pyruvate} + {H_{2}O_{2}}}} & {{Eq}.\mspace{11mu} 1} \\\left. {H_{2}O_{2}}\rightarrow{O_{2} + {2\; H^{+}} + {2\; e^{-}\mspace{14mu}{response}\mspace{14mu}{reaction}\mspace{14mu}{of}\mspace{14mu}{the}\mspace{14mu}{CDP}}} \right. & {\;{{Eq}.\mspace{11mu} 2}}\end{matrix}$

When the hypoxia glycolysis (Eq. 2) is activated (the concentration ofO₂ is less than 5%) in cancer cells, increased reactive oxygen species(ROS) generated by mitochondria, would significantly enhance thecathodic peak of an electrochemical response measured from thesuspicious sample which could be sharply detected by VAMWCNTs 130electrodes. It may be known that the lactate released by hypoxic tumorcells during their glycolysis may not be discharged as a waste product,but may be taken up by oxygenated tumor cells as energy fuel in whichLactate is converted to pyruvate and H₂O₂ by LDH-B and then enters themitochondria for OXPHOS to generate ATP. Similar to this process, thelactate released from hypoxic tumor cells may be used herein inelectrochemical assay to trace the concentration of lactate due to theintensity of the H₂O₂ produced during LADH (Eq. 1) and releasedelectrons due to the intensity of H₂O₂ oxidation reaction (Eq. 2).

FIG. 3B shows a schematic overview of mitochondrial electron and protonfluxes in hypoxia, consistent with one or more exemplary embodiments ofthe present disclosure. During normaxia, electrons released from reducedcofactors (NADH and FADH2), flow through the redox centers of therespiratory chain (r.c.) to molecular oxygen (dotted lines), to which aproton flux from the mitochondrial matrix to the intermembrane space iscoupled (grey arrows). Protons then flow back to the matrix through theF0 sector of the ATP synthase complex, driving ATP synthesis. ATP iscarried to the cell cytosol by the adenine nucleotide translocator (greyarrows). Under moderate to severe hypoxia, electrons escape the r.c.redox centers and reduce molecular oxygen to the superoxide anionradical before reaching the cytochrome c (black arrows). Under theseconditions, to maintain an appropriate Δψm, ATP produced by cytosolicglycolysis enters the mitochondria where it is hydrolyzed by the FIFOATPase with extrusion of protons from the mitochondrial matrix (blackarrows). So, the mechanism of H₂O₂ detection by the VAMWCNTs 130electrodes in hypoxia glycolysis may be based on released ion speciesduring reduction of NADH⁺, generation of ROS and production ofsuperoxide anion radical by reducing molecular oxygen before reaching tocytochrome c. The amount of released charged species and increasedcurrent transferred by VAMWCNTs 130 electrodes may be correlated withthe concentration of the lactate and subsequently H₂O₂ which resulted inROS generated during hypoxia glycolysis.

FIG. 1N shows a computer system 114A in which an embodiment of thepresent disclosure, or portions thereof, may be implemented ascomputer-readable code, consistent with exemplary embodiments of thepresent disclosure. For example, steps 204-212 of flowchart 200, steps224 and 226 of flowchart 220, steps 270-274 of flowchart 226, and steps280-286 of flowchart 270 may be implemented in computer system 114Ausing hardware, software, firmware, tangible computer readable mediahaving instructions stored thereon, or a combination thereof and may beimplemented in one or more computer systems or other processing systems.Hardware, software, or any combination of such may embody any of themodules and components in FIGS. 1A-1M. In an exemplary embodiment,computer system 114A may include processor 114.

If programmable logic is used, such logic may execute on a commerciallyavailable processing platform or a special purpose device. One ordinaryskill in the art may appreciate that an embodiment of the disclosedsubject matter can be practiced with various computer systemconfigurations, including multi-core multiprocessor systems,minicomputers, mainframe computers, computers linked or clustered withdistributed functions, as well as pervasive or miniature computers thatmay be embedded into virtually any device.

For instance, a computing device having at least one processor deviceand a memory may be used to implement the above-described embodiments. Aprocessor device may be a single processor, a plurality of processors,or combinations thereof. Processor devices may have one or moreprocessor “cores.”

An embodiment of the invention is described in terms of this examplecomputer system 500. After reading this description, it will becomeapparent to a person skilled in the relevant art how to implement theinvention using other computer systems and/or computer architectures.Although operations may be described as a sequential process, some ofthe operations may in fact be performed in parallel, concurrently,and/or in a distributed environment, and with program code storedlocally or remotely for access by single or multi-processor machines. Inaddition, in some embodiments the order of operations may be rearrangedwithout departing from the spirit of the disclosed subject matter.

Processor device 11404 may be a special purpose or a general-purposeprocessor device. As will be appreciated by persons skilled in therelevant art, processor device 11404 may also be a single processor in amulti-core/multiprocessor system, such system operating alone, or in acluster of computing devices operating in a cluster or server farm.Processor device 11404 may be connected to a communicationinfrastructure 11406, for example, a bus, message queue, network, ormulti-core message-passing scheme.

In an exemplary embodiment, computer system 114A may include a displayinterface 11402, for example a video connector, to transfer data to adisplay unit 11430, for example, a monitor. Computer system 114A mayalso include a main memory 11408, for example, random access memory(RAM), and may also include a secondary memory 11410. Secondary memory11410 may include, for example, a hard disk drive 11412, and a removablestorage drive 11414. Removable storage drive 11414 may include a floppydisk drive, a magnetic tape drive, an optical disk drive, a flashmemory, or the like. Removable storage drive 11414 may read from and/orwrite to a removable storage unit 11418 in a well-known manner.Removable storage unit 11418 may include a floppy disk, a magnetic tape,an optical disk, etc., which may be read by and written to by removablestorage drive 11414. As will be appreciated by persons skilled in therelevant art, removable storage unit 11418 may include a computer usablestorage medium having stored therein computer software and/or data.

In alternative implementations, secondary memory 11410 may include othersimilar means for allowing computer programs or other instructions to beloaded into computer system 114A. Such means may include, for example, aremovable storage unit 11422 and an interface 11420. Examples of suchmeans may include a program cartridge and cartridge interface (such asthat found in video game devices), a removable memory chip (such as anEPROM, or PROM) and associated socket, and other removable storage units11422 and interfaces 11420 which allow software and data to betransferred from removable storage unit 11422 to computer system 114A.

Computer system 114A may also include a communications interface 11424.Communications interface 524 allows software and data to be transferredbetween computer system 114A and external devices. Communicationsinterface 11424 may include a modem, a network interface (such as anEthernet card), a communications port, a PCMCIA slot and card, or thelike. Software and data transferred via communications interface 11424may be in the form of signals, which may be electronic, electromagnetic,optical, or other signals capable of being received by communicationsinterface 11424. These signals may be provided to communicationsinterface 11424 via a communications path 11426. Communications path11426 carries signals and may be implemented using wire or cable, fiberoptics, a phone line, a cellular phone link, an RF link or othercommunications channels.

In this document, the terms “computer program medium” and “computerusable medium” are used to generally refer to media such as removablestorage unit 11418, removable storage unit 11422, and a hard diskinstalled in hard disk drive 11412. Computer program medium and computerusable medium may also refer to memories, such as main memory 11408 andsecondary memory 11410, which may be memory semiconductors (e.g. DRAMs,etc.).

Computer programs (also called computer control logic) are stored inmain memory 11408 and/or secondary memory 11410. Computer programs mayalso be received via communications interface 11424, Such computerprograms, when executed, enable computer system 114A to implementdifferent embodiments of the present disclosure as discussed herein. Inparticular, the computer programs, when executed, enable processordevice 11404 to implement the processes of the present disclosure, suchas the operations in method 200 illustrated by flowchart 200 of FIGS. 2Aand 2D, flowchart 220 of FIG. 2E, flowchart 226 of FIG. 2I, andflowchart 270 of FIG. 2J discussed above. Accordingly, such computerprograms represent controllers of computer system 114A. Where anexemplary embodiment of method 200 is implemented using software, thesoftware may be stored in a computer program product and loaded intocomputer system 114A using removable storage drive 11414, interface11420, and hard disk drive 11412, or communications interface 11424.

Embodiments of the present disclosure also may be directed to computerprogram products including software stored on any computer useablemedium. Such software, when executed in one or more data processingdevice, causes a data processing device to operate as described herein.An embodiment of the present disclosure may employ any computer usableor readable medium. Examples of computer useable mediums include, butare not limited to, primary storage devices (e.g., any type of randomaccess memory), secondary storage devices (e.g., hard drives, floppydisks, CD ROMS, ZIP disks, tapes, magnetic storage devices, and opticalstorage devices, MEMS, nanotechnological storage device, etc.).

The embodiments have been described above with the aid of functionalbuilding blocks illustrating the implementation of specified functionsand relationships thereof. The boundaries of these functional buildingblocks have been arbitrarily defined herein for the convenience of thedescription. Alternate boundaries can be defined so long as thespecified functions and relationships thereof are appropriatelyperformed.

EXAMPLE 1: FABRICATION OF CNT BASED ELECTROCHEMICAL CHIP FOR IN VITROASSAYS

In this example, exemplary CNT based electrochemical chips wasfabricated for in vitro assays. First, silicon wafer (p-type <100>)substrates were cleaned through standard RCA #1 method (NH₄OH:H₂O₂:H₂Osolution and volume ratio of 1:1:5 respectively). Then, the cleanedsubstrates were rinsed in deionized (DI) water and dried by air. A thinlayer of SiO₂ with a thickness of about 200 nm was grown by wetoxidation furnace on the surface of the silicon wafer, as a passivationlayer. Nickel (Ni) catalyst layer for CNT growth with a thickness ofabout 9 nm was coated on SiO₂ by E-beam evaporation system at atemperature of about 120° C. with depositing rate of about 0.1Angstroms/s. Afterwards, Ni-covered samples were located in a directcurrent plasma enhanced chemical vapor deposition (DC-PECVD) system togrow vertically aligned multi-walled carbon nanotubes (VAMWCNT). Thegrowth process has three steps, including annealing, graining andgrowth. At first, the sample was annealed at a temperature of about 680°C. in an H₂ environment with a flow rate of about 35 standard cubiccentimeters per minute (sccm) for about 30 minutes. During the graining,the surface was plasma hydrogenated for about 5 minutes with theintensity of about 5.5 W·cm² which results in the catalyst graining andformation of Ni nano-sized islands. In the growth step a plasma of C₂H₂and H₂ mixture with flow rates of about 5 sccm and about 35 sccm wereintroduced to the chamber for about 15 minutes. Finally, CNT's werecharacterized with field emission scanning electron microscopy (FESEM).The length of CNTs ranged from about 2.5 to about 5 μm and the diameterof CNTs ranged from about 50 nm to about 70 nm.

FIG. 4 shows the FESEM image of the VAMWCNTs array on a portion of anexemplary fabricated CNT based electrochemical chip, consistent with oneor more exemplary embodiments of the present disclosure. The CNTs weremulti-walled carbon nanotubes with high purity and a presence of nickelon the top side of the CNTs could be related to the tip-growthmechanism. The CNT has been used as the work, counter and referenceelectrodes in exemplary fabricated CNT based electrochemical chips. Theactive area of the work, counter and reference electrodes were about 100mm², 100 mm, 50 mm², respectively. The CNT based electrochemical chipswere connected to a potentiostat by conductive wires bonded to the padsof the potentiostat.

EXAMPLE 2: FABRICATION OF CANCER DIAGNOSTIC PROBE (CDP) FOR IN VIVOASSAYS

In this example, the tips of sterile steel needles were coated by Nicatalyst layers similar to that was described in EXAMPLE 1 for CNT basedelectrochemical chips with the assistance of E-Beam coating system. Afixture was designed and fabricated to hold the needles both in E-Beamand DC-PECVD systems to limit the growth of CNTs just in the tips of theneedles. Then, the CNT grown needles were attached to electricalconnectors with three pins by a conductive paste. Just tips of theneedle were extended from the connectors up to about 1 cm. The probe wasreinforced with a homemade holder and connected to a readout system by anoiseless cable which handled all three electrodes.

FIGS. 5A-5D show FESEM images of a tip of a needle electrode of anexemplary fabricated cancer diagnostic probe (CDP) coated with an arrayof VAMWCNTs on the tip and exemplary portions 501, 502 and 503 of thetip, consistent with one or more exemplary embodiments of the presentdisclosure. FIG. 5A illustrates a FESEM image of the tip of a needleelectrode of an exemplary fabricated cancer diagnostic probe (CDP)coated with the array of VAMWCNTs on the tip, consistent with one ormore exemplary embodiments of the present disclosure. FIG. 5Billustrates a FESEM image of portion 501 of the tip, consistent with oneor more exemplary embodiments of the present disclosure. FIG. 5Cillustrates a FESEM image of portion 502 of the tip, consistent with oneor more exemplary embodiments of the present disclosure. FIG. 5Dillustrates a FESEM image of portion 503 of the tip, consistent with oneor more exemplary embodiments of the present disclosure.

EXAMPLE 3: CV OF H₂O₂ CONTAINED LACTATE SOLUTION

In this example, the cyclic voltammetry (CV) diagram of L-lactic acidsolution individually were recorded by exemplary electrochemical sensorsincluding working electrodes (WEs) fabricated from platinum (Pt), Gold(Au), amorphous glassy carbon (GC) and carbon nanotube (CNT).

FIG. 6A shows the CV diagrams of L-lactic acid solution individuallyrecorded by electrochemical sensors fabricated from platinum (Pt) (curve620), Gold (Au) (curve 630), amorphous glassy carbon (GC) (curve 640),and carbon nanotube (CNT) working electrodes (WEs) (curve 650),consistent with one or more exemplary embodiments of the presentdisclosure. It may be observed that the detected cathodic peak by CNT WEwas so sharper (about 1500 μA) in similar concentration of H₂O₂ withrespect to other electrodes (about 717, 5.7 and 0.8 μA in Au, Pt and GCelectrodes, respectively). CNT greatly transfer the released chargesfrom oxidized H₂O₂ beneath the nanotubes in media solution. Hence, CNTarrays were used as electrodes of exemplary sensors in the presentdisclosure.

FIG. 6B shows the CV diagrams of solutions with various concentrationsof lactate (and subsequently H₂O₂) recorded by electrochemical sensorswith CNT arrays working electrode, consistent with one or more exemplaryembodiments of the present disclosure. CV diagrams were recorded forsolutions with a lactate concentration of about 0.025 mM (CV diagram602), 0.05 mM (CV diagram 604), 0.1 mM (CV diagram 606), and 0.3 mM (CVdiagram 608). CNT working electrode presented a well concentrationdepended increased response to the presence of lactate molecules in thesolutions ranged from about 0.025 mM (CV diagram 602) to about 0.3 mM(diagram 608).

FIG. 6C shows the CV diagrams of H₂O₂ contained lactate solution with alactate concentration of about 0.3 mM (CV diagram 614) in comparisonwith two cell culture solutions RPMI (CV diagram 610) and DMEN (CVdiagram 612) recorded by electrochemical sensors with CNT arrays workingelectrode, consistent with one or more exemplary embodiments of thepresent disclosure. It may be observed that RPMI and DMEN cell culturesolutions show less electrochemical responses in comparison with H₂O₂contained lactate solution. The RPMI presented no electrochemicalresponses in the voltage attributed to the lactate detection. As aresult, RPMI could be applied as cellular and tissue culture media witha negligible false positive response.

EXAMPLE 4: ELECTROCHEMICAL RESPONSES OF DIFFERENT CELL LINES

In this example, electrochemical sensing of H₂O₂ produced duringLactate/Pyruvate hypoxic glycolysis was verified in four differentphenotypes of breast cell lines ranged from normal to malignant stages,including: MCF10 A, MCF-7, MDA-MB-231, and MDA-MB-468. Breast cancercell lines (MCF10A, MCF-7, MDA-MB-231, MDA-MB-468) were obtained andwere maintained at 37° C. (5% CO₂, 95% air) in RPMI medium supplementedwith 5% fetal bovine serum, and 1% penicillin/streptomycin. The freshmedium was replaced every other day. All cell lines were tested andfound negative for Mycoplasma contamination. The cells were detachedfrom the plates by trypsin and counted by neobar laam.

FIG. 7 shows the CV responses of normal (MCF10A: CV diagram 702) anddifferent grades of cancerous (MCF7: CV diagram 706, MDA-MB231: CVdiagram 708, and MDA-B468: CV diagram 710) breast cells' solution mediacultured for about 48 hours in comparison with standard H₂O₂ containedlactate solution with a lactate concentration of about 0.3 mM (CVdiagram 712) and RPMI (CV diagram 704) in individual sensing wells ofexemplary fabricated sensor in EXAMPLE 1 herein above, consistent withone or more exemplary embodiments of the present disclosure. Lactateproduction due to hypoxic glycolysis would be well detectable afterabout 48 hours of incubation in cancer cell lines. The CV diagrams ofFIG. 7 show that the intensity of oxidation peak, located at theposition of H₂O₂ electrochemical response, significantly increased withthe progression in invasive grades of cancer cells in which hypoxiaglycolysis would be enhanced.

Referring to FIG. 6B and FIG. 7, sharp difference in electrochemicalpeaks of H₂O₂ contained lactate solution was observed from about 0.025mM to about 0.05 mM which could be applied to calibrate cancer cells'media from normal ones. Because the electrochemical responses of cancercells' media solution was equal to the response range of H₂O₂ containedlactate solution with the concentration of more than about 0.05 mMmeanwhile such response in normal cells was equal to the response rangeof the H₂O₂ contained lactate solution with the concentration of lessthan about 0.025 mM.

Moreover, similar responses were recorded from the culture media ofcolon, prostate, liver, lung, mouth, neural and hematopoietic cell linesin normal and cancer phenotypes with invasive and moderate grades byelectrochemical sensing of H₂O₂ produced during Lactate/Pyruvate hypoxicglycolysis for some other types of colon, neural, prostate, liver,mouth, hematopoietic and lung cell lines. Colon (COR-L 105, SW-480,HT-29), Hematopoietic (1301, LCL-PI 1), Liver (HEP G2), Lung (QU-DB,MRC-5), Mouth (KB), Neuron (BE(2)-C, LAN-5), Prostate (PC-3, Du-145)cell lines were obtained and were maintained at 37° C. (5% CO₂, 95% air)in RPMI medium supplemented with 5% fetal bovine serum, and 1%penicillin/streptomycin. The fresh medium was replaced every other day.All cell lines were tested and found negative for Mycoplasmacontamination. The cells were detached from the plates by trypsin andcounted by neobar laam.

FIGS. 8A-8G shows the CV responses of the solution media of differentnormal and cancerous cell lines in various phenotypes including Colon(COR-L 105 802, SW-480 803, IT-29 804) in FIG. 8A, Hematopoietic (1301805, LCL-P11 806) in FIG. 8B, Liver (HEP G2 807) in FIG. 8C, Lung (QU-DB808, MRC-5 809) in FIG. 8D, Mouth (KB 810) in FIG. 8E, Neuron (BE(2)-C,LAN-5) in FIG. 8F, and Prostate (PC-3 813, Du-145 814) in FIG. 8G celllines in comparison with Reference diagram 801 for H₂O₂ containedlactate solution with a lactate concentration of about 0.3 mM,consistent with one or more exemplary embodiments of the presentdisclosure. The current peaks in cancerous samples were observablyincreased. The H₂O₂ based oxidative peaks of cancer media solutions weresharper than that in normal cells. Grade dependent increase was observedin H₂O₂ peaks of cancer cells with sharp difference between normal andcancer phenotypes in all of the cell lines. This reveal the increasedhypoxia glycolysis in cancer cells with respect to that in normal cells.A great correlation was observed between the cells' phenotypes and theirlactate based H₂O₂ electrochemical responses.

EXAMPLE 5: IN VITRO DIAGNOSIS OF CANCER IN SAMPLES BY ELECTROCHEMICALTRACKING OF HYPOXIA GLYCOLYSIS IN SECRETION OF THE SAMPLES

In this example, the electrochemical responses of 6 breast tissuesremoved by biopsy (core needle biopsy (CNB)) or surgery from 6 ofsuspicious patients to cancer were analyzed using exemplary CNT basedelectrochemical chip. The size of the removed samples was similar (withthe non-dehydrated weight of about 25 mg). The electrochemical responseswere compared with cytopathological analysis done by Hematoxylin andEosin (H & E) staining of the 6 breast tissues. Each resected sample wasmaintained in RPMI for about 24 hours before analyzing by exemplary CNTbased electrochemical chip to be ensured from the lactate release inhypoxic tumors. Before pathological assaying, each resected sample wasfixed in Formaline. For electrochemical analysis of hypoxia glycolysisin secretion of the samples, live spices from CNB or surgically removedsamples were cut in similar specimens and directly transferred throughsensing wells of exemplary CNT based electrochemical chip containingRPMI-1640 without any preprocessing. About 24 hours after maintainingthe samples in incubator, about 200 μl of the culture media was droppedto individual sensing wells and the cathodic current of electrochemicalresponses of H₂O₂ were recorded in CV profile.

FIGS. 9A-9F show the cytopathological results (H&E images) (top side)and electrochemical responses (bottom side) of the breast tissuesremoved by biopsy or surgery from 6 suspicious patients to cancer,consistent with one or more exemplary embodiments of the presentdisclosure. The electrochemical responses were calibrated based on thereference H₂O₂, contained lactate solution with a lactate concentrationof about 0.3 mM as used for cell lines in EXAMPLE 4 above. The intensityof oxidation peak and released electrons strongly correlated to thelactate produced by hypoxia glycolysis in cancer cells. A wellcorrelation could be observed between increased H₂O₂ dependent currentpeak and cancer transformed morphology of the tissues. A great matchobserved between the quantified electrochemical response andpathological result of the samples in which the normal and hyperplastictissues expressed low levels of H₂O₂ related current peak meanwhile thecancerous tissues exhibited high levels of H₂O₂ related electrochemicalpeaks. Accordingly, FIGS. 9A-9C show results obtained from non-canceroussamples and FIGS. 9D-9F show results obtained from cancerous samples.

Similar electrochemical responses of 5 more samples, including livespices from CNB or surgically removed samples, were obtained usingexemplary CNT based electrochemical chip. FIG. 10 shows a columnardiagram of electrochemical responses of the breast tissues removed bybiopsy or surgery from 11 suspicious patients to cancer, consistent withone or more exemplary embodiments of the present disclosure. Referringto this figure, two regimes 1002 and 1003 of responses were achieved dueto the trace of hypoxia glycolysis based on LADH in comparison with areference state 1001 of a H₂O₂ contained lactate solution with a lactateconcentration of about 0.3 mM. In regime 1 indicated by 1002, theoxidation peaks were ranged from about 933.9 μA to about 1068.9 μA, andin regime 2 indicated by 1003, the oxidation peaks were ranged fromabout 269.6 μA to about 718 μA. The pathological results showed a wellcorrelation with this determination. The samples presented high levelsof hypoxia related oxidative peaks (categorized in regime 1) wereverified as cancer in their H&E assays. Nests of distinguished tumoralcells in H&E images of those patients could be observed in FIGS. 9D-9F.Such responses were observed in the H₂O₂ contained lactate solution withthe concentration of more than about 0.05 mM (FIG. 6B). Samples with lowlevels of lactate (regime2) were diagnosed as non-cancer with differenttypes of benign cancer patients such as hyperplasia (peak: 556.5 μA) inFIG. 9B, lactational changes (peak: 718 μA), and so on. Theseelectrochemical responses were equal to the peak determined in H₂O₂contained lactate solution with the concentration of less than about0.025 mM (FIG. 6B). Comparative columnar diagram presented in FIG. 10would elaborate the difference in lactate based electrochemical responsebetween normal and cancer tissues.

EXAMPLE 6: STANDARD COLORIMETRIC LACTATE ASSAY KIT

As the released H₂O₂ concentration have a direct correlation with lactaeconcentration, to further investigate the accuracy of exemplaryelectrochemical method described above, the results of both cell lines(described in EXAMPLE 4) and patients' samples (described in EXAMPLE 5)were compared by standard colorimetric lactate assay kit. Although thismethod is so time consuming and expensive with complicated multisequential steps, it was conducted to check the reliability of lactateconcentration based cancer diagnosis measured by exemplary CNT basedelectrochemical chip. Comparative responses versus reference H₂O₂contained lactate solution for both electrochemical and Lactate Kitassays are presented in Table 1 and Table 2.

TABLE 1 Comparative responses of CNT based electrochemical chip andstandard Lactate Kit Assay on 4 different phenotypes of Breast celllines. Electrochemical Lactate kit: sensor: Relative Relative LactateCell line Current (%) Concentration (%) Reference lactate 100 100solution MCF 10A 31.1 31.1 MCF-7 52.9 56.3 MDA-MB-231 69.5 70.9MDA-MB-468 91.5 91.5

TABLE 2 Diagnostic results of 11 patients suspicious to breast cancerdetermined by H&E, Lactate kit, and the cathodic peaks of released H₂O₂from the cells measured by CNT based electrochemical chip assays,respectively. CNT Lactate Kit Electrochemical Patient ID Type of TissueH & E Result Result (%) Sensor (%) Reference lactate — — 100 100solution 1 Normal Non Cancer 22.2 22.2 2 Normal Left Hyper Plasy 42.342.3 3 Normal Lactational Change 59.1 59.2 4 Normal Adenosis benign 53.853.7 glandular prolifration 5 Normal Hyperplasy and 45.9 45.9inflammation 6 Suspicious to Cancer Lympho vascular 88.1 88.2 invasion 7Suspicious to Cancer Cancer 77.2 77.2 8 Suspicious to Cancer Cancer 85.585.4 9 Suspicious to Cancer Cancer 80.5 80.5 10 Suspicious to CancerCancer 85.1 85.2 11 Suspicious to Cancer Cancer 62 62.2

A correlation was observed between the responses of the CNT basedelectrochemical chip and kit which revealed the accuracy of CNT basedelectrochemical chip in lactate based cancer detection as shown in Table1 and Table 2. The raw values recorded by Lactate kit andelectrochemical sensing wells were presented in these tables. Insummary, tracing the hypoxia glycolysis (correlated with lactateconcentration) in the interstitial fluid of biopsy sample byelectrochemical assay with suitable electrode (such as CNT) exhibited ahigh correlation with their pathological states and may be used as anewmethod in cancer diagnosis.

EXAMPLE 7: INTEGRATED ASSAY ON THE TIN OF THE NEEDLES OF CANCERDIAGNOSTIC PROBE (CDP) FOR REAL-TIME CANCER DETECTION BOTH IN VITRO ANDIN VIVO

To extend the application of exemplary label free electrochemical methodof the present disclosure in real-time and precise detection of thetumor tissues during interventional sonography or surgery, exemplary CDPfabricated by growth of carbon nanostructures on the tip of the sterilesteel needles as described in EXAMPLE 2 was used herein. Such integratedsystem contains three carbonated needles as working electrode (WE),counter electrode (CE), and reference electrode (RE). The needles wererinsed by PBS, Ethanol 70% and DI water followed by drying in N₂ ambientand UV sterile to prevent from any detachment and remaining the residuesof the nanotubes in the tissue. CV responses were taken immediatelyafter squeeze of exemplary CDP into the breast cancerous and normaltissues that indicated sharp increase in the current peak of the CDPwith CNT covered electrodes interacted by cancer tissue. The importantpoint is that the diagnosis was completed in live time based onmonitoring the lactate concentration of the tissues inner domain.

FIG. 11A shows CV response of exemplary CDP with all three needlescovered by VAMWCNTs immediately after connection to the tissues,consistent with one or more exemplary embodiments of the presentdisclosure. It may be observed that reversible shapes with symmetricanodic and catholic peaks were obtained in CV responses. Distinguishableresponse between normal and cancer tissues may be observed.

FIG. 11B shows CV response of exemplary CDP with only working electrodecovered by VAMWCNTs immediately after connection to the tissues,consistent with one or more exemplary embodiments of the presentdisclosure. Quality of the peaks were degraded when replacing the RE andCE by steel needle. The intensity and symmetry of the responses weredegraded in the sensor with just CNT covered WE (CE and RE were steelneedles).

FIG. 11C shows CV response of exemplary CDP with non-CNT covered byneedles immediately after connection to the tissues, consistent with oneor more exemplary embodiments of the present disclosure. There may beobserved a noisy response without any distinguishable electrochemicalpeak. When all of the electrodes were non CNT covered needles, theresponses were completely degraded and not distinguishable betweennormal and cancer tissues. This revealed the important role of CNT inselective interaction and charge transfer from the H₂O₂ released duringtransformation of lactate to pyruvate.

FIGS. 12A-12E show CV responses recorded by exemplary CDP (needle basedelectrochemical sensor) from the resected tissues from five patientsamong 50 individual patients suspicious to breast cancer at the bottomside of FIGS. 12A-12E in comparison with images obtained by conventionalpathological methods (H&E) at the top side of FIGS. 12A-12E, consistentwith one or more exemplary embodiments of the present disclosure.Patients respective to FIGS. 12A-12C have normal/non-cancerous (FIG.12A), hyperplastic (FIG. 12B), and adenosis glandular proliferativetissues (FIG. 12C). Patients respective to FIGS. 12D and 12E have cancertissues. Electrochemical current peaks of cancer tissues are sharply(more than about 150 μm) higher than benign ones with a strongcorrelation by the abundance of distributed cancer cells. The CVresponses recorded from the normal and cancer tissues of these 50individual patients by CNT covered needle sensors (CDP) greatly detectedthe hypoxic glycolysis just in cancerous samples due to cathodic peaksof H₂O (FIGS. 12A-12E). Meanwhile, while the response time of CDP wasless than about 1 minute after the tissue resection, diagnosis byconventional pathological methods (H&E) requires at least several hoursfor sample fixation and staining procedures. The ratio of cathodic peaksof reference H₂O₂ contained lactate solution vs. non-cancerous tissueswere more than three times (FIGS. 12A-12C) while such ratio was lessthan one time in cancerous tissues (FIGS. 12D and 12E).

Table 3 shows the results recorded by exemplary CDP in comparison withthe results obtained by H&E analysis from live resected tissues of 50patients suspicious to breast cancer. They exhibited great correlationswith the pathological results of the samples assayed by H&E method.

TABLE 3 Results recorded by exemplary CDP in comparison with the resultsobtained by H&E analysis from live resected tissues of 50 patientssuspicious to breast cancer. Oxidation Patient Current CDP ID Peaks (μA)(Cancer) H&E (Cancer) 1 0 Negative NO 2 46.6 Negative NO 3 87 NegativeNO 4 316.5 Positive YES (Cancer 90%, Normal 10%) 5 287.8 Positive YES(Cancer 90%, Normal 10%) 6 22 Negative NO 7 142.3 Positive YES (Cancer30%, Normal 70%) 8 150 Positive YES (Cancer 30%, Normal 70%) 9 300Positive YES (Cancer 90%, Normal 10%) 10 13 Negative NO 11 0 Negative NO12 101.5 Positive YES (Cancer 30%, Normal 70%) 13 180.2 Positive YES(Cancer 60%, Normal 40%) 14 289.4 Positive YES (Cancer 90%, Normal 10%)15 302 Positive YES (Cancer 90%, Normal 10%) 16 274.2 Positive YES(Cancer 90%, Normal 10%) 17 0 Negative NO 18 142.8 Positive YES (Cancer30%, Normal 70%) 19 80 Negative NO 20 32.5 Negative NO 21 200 PositiveYES (Cancer 60%, Normal 40%) 22 188.2 Positive YES (Cancer 60%, Normal40%) 23 264.5 Positive YES (Cancer 90%, Normal 10%) 24 23 Negative NO 25179.5 Positive YES (Cancer 60%, Normal 40%) 26 55.2 Negative NO 27 52Negative NO 28 77 Negative NO 29 0 Negative NO 30 201 Positive YES(Cancer 60%, Normal 40%) 31 75.6 Negative NO 32 155.8 Positive YES(Cancer 30%, Normal 70%) 33 99.5 Positive YES (Cancer 30%, Normal 70%)34 305.5 Positive YES (Cancer 90%, Normal 10%) 35 297.7 Positive YES(Cancer 90%, Normal 10%) 36 112 Positive YES (Cancer 30%, Normal 70%) 3717.8 Negative NO 38 40 Negative NO 39 73 Negative NO 40 290 Positive YES(Cancer 90%, Normal 10%) 41 90 Positive YES (Cancer 30%, Normal 70%) 42330 Positive YES (Cancer 90%, Normal 10%) 43 197.5 Positive YES (Cancer30%, Normal 70%) 44 77.5 Negative NO 45 25 Negative NO 46 266.2 PositiveYES (Cancer 90%, Normal 10%) 47 0 Negative NO 48 102.5 Positive YES(Cancer 30%, Normal 70%) 49 310 Positive YES (Cancer 90%, Normal 10%) 50259.3 Positive YES (Cancer 90%, Normal 10%)

FIG. 13 shows a summary of categorized regimes of CV responses recordedby exemplary CDP from the resected tissues from five patients among 50individual patients suspicious to breast cancer that were presented inTable 3. It represents CV regimes along a spectrum from a completelynon-cancerous state to cancerous state, consistent with one or moreexemplary embodiments of the present disclosure. It may be seen that ifthe H₂O₂ cathodic peak (equal to oxidation current peak) of exemplary CVresponse recorded by exemplary CDP from a patient is less than 90 μA,the tissue is in non-cancerous state. On the other hand, if the CVresponse recorded by exemplary CDP from the tissue is in a range morethan about 95 μA, there exists a cancerous state which may be moreintensified by increasing the oxidation current peak. A range ofoxidation current peak between 90 μA and 95 μA is the border range.

EXAMPLE 8: IN VIVO ANALYSIS OF OBSERVABLE TUMOR WITH HISTOLOGICALLYDISTINCT CANCER MARGIN BEFORE ANY MASTECTOMY

To determine if CDP would in real time identify an observable tumor invivo, about 2.3×10⁶ 4T1-derived cancer cells were implanted into theback of 10 female BALB/C mice, and the mice were maintained inindividual groups with similar size of formed tumors with sharphistologically distinct patterns. After about 10 days, individual CDPswere externally squeezed into their cancerous and normal regions hadbeen specified by sonography. The space between each assayed regions wasabout 3 mm. Also the mice under body were connected to ground potentialsuch as done for any patient in surgery room.

FIG. 14A shows a sonography image from a tumor side taken from anexemplary mouse tumorized by 4T1 breast cancer cell lines, consistentwith one or more exemplary embodiments of the present disclosure. Atumor with average sizes with a length 1402 of about 2.24 cm and anotherlength 1404 of about 1.60 cm could be observed in sonography image.

FIG. 14B shows H&E image from the tumor side taken from exemplarytumorized mouse by 4T1 breast cancer cell lines, consistent with one ormore exemplary embodiments of the present disclosure. FIG. 14C shows H&Eimage from a normal/healthy side taken from exemplary tumorized mouse by4T1 breast cancer cell lines, consistent with one or more exemplaryembodiments of the present disclosure.

FIG. 14D shows CV diagrams of normal and tumor regions/sides ofexemplary tumorized mouse by 4T1 breast cancer cell lines calibrated bya Reference CV diagram from H2O2 contained lactate solution with alactate concentration of about 0.3 mM obtained using exemplary CDP,consistent with one or more exemplary embodiments of the presentdisclosure. It may be observed that the lactate related peaks were about3 times higher in cancer region (CV diagram 1406 and FIGS. 14A and 14B)versus normal ones (CV diagram 1408 and FIG. 14C). Sharp lactateelectrochemical peaks were observed in tumor locations by about threetimes higher current than that recorded from their normal regions

To more clearly clarify the impact of H₂O₂ monitoring in tumor growthand progression, tumor size effects on H₂O₂ related electrochemicalpeaks recorded by CDP were compared. A distinguishable increasing regimewas observed in the intensity of current peak through increment in thetumor size. Moreover, Histopathological images taken from the normal andcancer regions detected by CDP confirmed this result. Hyper chromaticand irregular nucleus with increased nucleus/cytoplasm ratio may beobservable in H&E images of cancer region.

EXAMPLE 9: IN VIVO ANALYSES OF SUSPICIOUS REGIONS BEFORE AND DURING THESURGERY

In this example, the ability of the CDP to distinguish suspiciousregions to cancer in mice model was analyzed by the resolution of about3 mm which could be translated to human model. Tissue samples thatcontained regions of invasive breast cancer adjacent to normal stromawere experimented.

Five tumorized mice by 4T1 breast cancer cell lines were checked bysonography. FIG. 15A shows a sonography image from a tumor 1501 takenfrom an exemplary mouse tumorized by 4T1 breast cancer cell lines,consistent with one or more exemplary embodiments of the presentdisclosure. Approximate dimensions of the tumor could be observed insonography image of FIG. 15A.

Exemplary CDP was tested on tumor and suspicious regions of the fivetumorized mice before (by squeezing through skin) and during the surgeryon exemplary six regions. FIGS. 15B and 15C show exemplary six analyzedregions 1502-1507 of an exemplary tumorized mouse among the exemplaryfive tumorized mice before (FIG. 15B) and during surgery (FIG. 15C),consistent with one or more exemplary embodiments of the presentdisclosure. Six analyzed regions may include center 1502 of tumor 1501,left side 1503 of tumor 1501, right side 1504 of tumor 1501, upside 1505of tumor 1501, bottom side 1506 of tumor 1501, and also an exemplarynormal side 1507 far from tumor 1501 all depicted in FIGS. 15B and 15Cwere analyzed consecutively before and during surgery using a CDP withan about 3 mm distance between needle electrodes.

Moreover, frozen H&E assay was used and rechecked by IHC method to beensure from the precision of CDP results with respect to standardprotocols. A tissue section of the sample including exemplary sixregions analyzed by exemplary CDP was subjected to frozen H&E stainingprocesses and evaluated by the pathologist. Exemplary tumor 1501containing suspicious regions was removed and sent for frozen pathologyand the H&E images taken from the center 1502 of tumor 1501 as well asits posterior 1505, anterior 1506, right 1504 and left 1503 lateralswith the distance of about 3 mm from the histologically distinct region,were demanded by the CDP results as presented in Table 4. The results ofCDP before and during surgery exhibited a perfect correlation. Ki67based IHC assay confirmed the normal state of R5 and cancer involvementin R3 as classifier reference.

TABLE 4 Results recorded by exemplary CDP before and during surgery incomparison with the results obtained by H&E analysis from six suspiciousregions of an exemplary tumorized mouse. CDP Before Surgery CDP DuringSurgery (Ox Current Peaks (Ox Current Peaks H&E frozen Region (μA))(μA)) (Cancer) 1502 (Center) Positive (169.104) Positive (178.621) Yes(Cancer 90%, Normal 10%) 1503 (Right) Positive (94.773) Positive (96.89)Yes (Cancer 30%, Normal 70%) 1504 (Left) Positive (122.643) Positive(122.8) Yes (Cancer 60%, Normal 40%) 1505 (Up) Negative (30.397)Negative (31.85) No 1506 (Bottom) Negative (0) Negative (0) No 1507(Normal) Negative (0) Negative (0) No

As represented in Table 4, it was distinguished from H&E analyzes thatcenter 1502 was diagnosed by frozen histopathology as cancer tissue,whereas regions 1505 and 1506 were diagnosed as normal stroma. Region1504 was in the margin between the cancer and normal stroma tissueregions, presenting about 40% tumor tissue and about 60% normal stromatissue. Region 1503 was a suspicious region without any tumor marginsbut the trace of distributed cancer cells would be observed betweenstroma. Tumoral cells would be distinguished due to their hyper chromicnuclei (triangular arrows in H&E images of regions 1503 and 1504).Tabled result shows the CDP obtained for regions 1502 and 1504 presentedsignificant hypoxic lactate peaks meanwhile lower but detectablemeaningful levels of the H₂O₂ was recorded for region 1503. Nodetectable trace of any peak was measured for region 1506. The CDPresponse obtained for 1507, diagnosed as reference normal stroma tissue,presented no H₂O₂ peak similar to that observed for 1506.

The CDP response obtained for regions 1504 and 1506 were then evaluatedby Ki67 IHC as an independent validation set. The expression of Ki67 hasbeen reported to be correlated with tumor cell proliferation and growthin routine pathological investigation and used as a diagnostic marker.Ki67 based IHC classifier identified no trace of cancer proliferation inregion 1506 (as the normal stroma) and showed different intensities offiltrated cancer cells in region 1504. Similar results were obtained for5 other animal models with suspicious regions in anterior, posterior,right and left laterals of their tumors.

In addition, exemplary CDP exhibited a fine distinguishable response ininteraction with another type of cancer tumors (MC4L2) as cancer cellswith lower invasive grades than 4T1 as experimented on mice models.Tumors formed by the injection of about 5×10⁵ MC4L2 cells (mice primarybreast cancer cell lines) were analyzed by exemplary CDP on 5 mice.

FIG. 16 shows comparative diagram of CDP responses in interaction withnormal (curve 1601), non-metastasized tumor (curve 1602) and metastatictumor (curve 1603) recorded from individual mice, consistent with one ormore exemplary embodiments of the present disclosure. Tracing thehypoxia glycolysis exhibited a strong correlation with the invasivestate of the tumor. Results revealed sharply distinguishable responsesbetween cancerous and normal regions. However the intensity of theresponse of MC4L2 tumors is lower than that was recorded for malignanttumor, it is observably higher than the response peak of normal tissue.

Furthermore, in this example, exemplary CDP was applied in finding thesuspicious margins during tumor resection surgery in breast cancerpatients. Not only the known normal domains were detected and set asreference point, but also suspicious margins of cancer and normaldomains were precisely diagnosed in real-time and confirmed byhistopathological assays. So, without requirement to frozen pathologicalprocess the surgeon can finish the surgery with insurance from preciseresection of tumor without any additional mastectomy from the peripheraltissues.

FIGS. 17A-17C shows CV responses obtained by applying exemplary CDP indetection of suspicious margins during breast cancer surgery for a knownnormal region (FIG. 17A) that was checked as calibrating data, and twosuspicious margins (FIGS. 17B and 17C) that were precisely diagnosed ascancerous (FIG. 17B) and normal (FIG. 17C) domains by CDP in real-time,consistent with one or more exemplary embodiments of the presentdisclosure. The results obtained by exemplary CDP were confirmed by H&Eanalysis. FIGS. 17D-17F shows H&E results after the surgery for theknown normal region, and two suspicious margins, consistent with one ormore exemplary embodiments of the present disclosure.

These results show that the diagnostic information obtained by exemplaryCDP can be used to detect cancer in marginal suspicious regions withrare distribution of cancer cells filtrated between normal stroma inless than about 20 seconds during the surgery or biopsy of live animalas well as human models without any requirement to tissue resection andpreparation for frozen pathology. Even it may detect the accuratelocation of cancer involved regions before surgery in superficialtumors. The precision of this method is as well as reported for H&E fromthe assayed regions.

EXAMPLE 10: PATHOLOGICAL CLASSIFICATION OF CURRENT PEAKS OBTAINED BY THEEXEMPLARY FABRICATED CDP

In this example, current peaks of 258 human fresh samples prepared from74 breast cancer patients (Biopsied or surgically removed) were recordedutilizing exemplary CDP 102. 258 human fresh samples were testedimmediately after dissection from the body (with the non-dehydratedweight of about 15-25 mg and size of up to about 1 cm². All threeintegrated needle electrodes of exemplary CDP 102, assembled on the headprobe (the exemplary sensing part 154), were entered into a targettissue of the 258 human fresh samples at the same time. The wholeprocess which may include replacing a previously used sensing part 154by removing the previously used sensing part 154 and connecting a newsensing part 154 (about 20 see), entering exemplary CDP 102 to thetarget tissue by inserting new sensing part 154 into a target locationwithin the target tissue, and recording a CV response with a currentpeak from the target location (about 15 sec due to synchronizedreal-time processing) would take place in less than about 40 seconds.The permanent pathological diagnostic results of the samples, which werere-checked by three histological slides from each sample, were a set ofreference data in probable scalability of the recorded CV responses.

Meaningful results were observed after comparing an experimentalcategorization of samples through their CDP recorded current peaks withtheir categorization through their H&E pathological diagnoses. Table 5shows CDP current peak results of 258 fresh samples from 74 patients inassociation with pathological diagnosis based on pathologicalclassification (DIN, LIN and FEL). Additionally, FIG. 18 shows H&Eimages 1802-1818 from nine exemplary samples associated with nineexemplary categories in Table 5, consistent with one or more exemplaryembodiments of the present disclosure.

TABLE 5 CDP current peak results of 258 fresh samples from 74 patientsin association with pathological diagnosis based on pathologicalclassification (DIN, LIN and FEL). Pathological Number of Pathologicalscoring for re- Ranges of the Diagnosis excising recorded Number matched(classification recommendation CDP peak of tested samples in system)(warning state) current (μA) samples CDP ranges Fatty breast tissueNegative  0-40 15 14 (FEL) Sclerosing adenosis Negative  83-115 11 8(DIN) FCC with CCC Negative 110-117 19 17 (DIN) Moderate usual Negative117-137 12 10 ductal hyperplasia (DIN) Florid ductal Negative 150-170 108 hyperplasia (DIN) (moderate risk) Stroma + one focus Negative 175-1965 4 of ADH (DIN) (moderate risk) Stroma + two or positive 203 -260 31 28more foci of ADH; DIN1b (DIN) Stroma + one foci positive 231-290 24 21of DCIS; DIN1c (DIN) IDC >5% positive 360 and more 19 19

It was observed that 26 samples among 258 samples were normal breaststroma, including fatty breast tissues and simple fibroadenoma, whichall showed current peaks in a range of about 0-83 μA as shown in Table5. Image 1802 of FIG. 18 shows H&E image from an exemplary sampleincluding fatty breast tissue (FEL) as a normal breast tissue with acurrent peak between about 0 μA and about 40 μA, consistent with one ormore exemplary embodiments of the present disclosure. 18 samples werenon proliferative fibrocystic changes (FCC) which all of them showedcurrent peaks in a range of about 53-111 μA. 10 samples were mild usualductal hyperplasia (UDH) which all of them showed current peaks in arange of about 83-110 μA. 11 samples were sclerosis adenosis (SA) which8 of them showed current peaks in a range of about 86-115 μA. Image 1804of FIG. 18 shows H&E image from an exemplary sample including sclerosisadenosis (SA) with a current peak between about 83 μA and about 115 μA,consistent with one or more exemplary embodiments of the presentdisclosure. 12 samples were moderate UDH which 10 of them showed currentpeaks in a range of about 120-137 μA. 19 samples were FCC with columnarcell changes (CCC) (some of them also had one foci suspicious toatypical ductal hyperplasia (ADH) which 17 of them showed current peaksin a range of about 110-173 μA. Image 1806 of FIG. 18 shows H&E imagefrom an exemplary sample including fibrocystic changes (FCC) withcolumnar cell changes (CCC) with a current peak between about 110 μA andabout 117 μA, consistent with one or more exemplary embodiments of thepresent disclosure. Image 1808 of FIG. 18 shows H&E image from anexemplary sample including Moderate usual ductal hyperplasia (DIN) witha current peak between about 117 μA and about 137 μA, consistent withone or more exemplary embodiments of the present disclosure. Image 1810of FIG. 18 shows H&E image from an exemplary sample including Floridductal hyperplasia (DIN) with a current peak between about 150 μA andabout 170 μA, consistent with one or more exemplary embodiments of thepresent disclosure. Image 1812 of FIG. 18 shows H&E image from anexemplary sample including stroma with one focus of atypical ductalhyperplasia (ADH) with a current peak between about 175 μA and about 196μA, consistent with one or more exemplary embodiments of the presentdisclosure. In summary, normal breast (e.g. breast fatty tissue), UDH(e.g. FCC lesions) and DIN1a (e.g. FCC with CCC and a small foci of ADH)showed response peak ranges from about 0 μA to about 196 μA which werenegatively scored by CDP.

Moreover, 31 samples showed involvement to two or more foci of ADH which28 of them showed peak currents in a range of about 203-250 μA. Image1814 of FIG. 18 shows H&E image from an exemplary sample includingstroma with two or more foci of ADH (DIN1b) with a current peak betweenabout 203 μA and about 2601 μA, consistent with one or more exemplaryembodiments of the present disclosure. 24 samples showed involvement tolow grade ductal carcinoma in-situ (DCIS), from about 10% to about 45%of the histological pattern, which 21 of those samples showed currentpeaks in a range of about 250-360 μA.

Image 1816 of FIG. 18 shows H&E image from an exemplary sample includingstroma with one foci of ductal carcinoma in-situ (DCIS) (DIN1c) with acurrent peak between about 231 μA and about 290 μA, consistent with oneor more exemplary embodiments of the present disclosure. 12 samples wereinvasive ductal carcinoma (IDCs) with distributions between 5-55% ofhistological pattern, which all of them showed current peaks in a rangeof about 610-800 μA. 2 samples were phylloids tumor which both showedpeak currents more than about 260 μA. Just 10 samples were found withlobular based atypia/neoplasia; 4 of those samples were invasive lobularcarcinoma (ILC) with extensive distribution which all showed currentpeaks in a range of about 380-465 μA. 4 samples were atypical lobularhyperplasia (ALH) which showed current peaks between in a range of about257-270 μA. 2 other samples were lobular carcinoma in-situ (LCIS) whichboth showed current peaks of about 290 μA. Image 1818 of FIG. 18 showsH&E image from an exemplary sample including invasive ductal carcinoma(IDC) with a current peak more than about 360 μA, consistent with one ormore exemplary embodiments of the present disclosure.

Considering the above pathological results and current peaks of thesamples together, a classification on CV responses recorded by exemplaryCDP 102 was proposed based on pathological diagnosis. The lowest cut-offfor pathologists on diagnosing a margin as positive (dissection ismandatory) is presence of at least two foci of ADH. Therefore, a borderline at about 203 μA was proposed as a cut-off current for positivescoring exemplary CDP 102. Samples consisting of ADH with more than twofoci, DCIS and IDCs most often showed peak currents higher than about203 μA while other samples consisting of one foci of ADH, UDH and FCClesions showed peak currents lower than about 196 μA. Hence, theresponses of exemplary CDP 102 were found to be classifiable based onnewest edition of ductal intraepithelial neoplasia (DIN), lobularintraepithelial neoplasia (LIN) and fibro-epithelial lesion (FEL)systems reported by world health organization (WHO). FIG. 19 showsclassification of current peaks recorded by exemplary CDP 102 afterexamining more than 250 samples in consistence with pathologicaldiagnosis, consistent with one or more exemplary embodiments of thepresent disclosure. It may be observed that samples with positivelyscored levels of glycolytic related H₂O₂ peaks were verified as ADH,DCIS, IDC and metastatic lymph nodes in their H&E assays showed morethan about 203 μA (as the cut-oft) in CDP response peaks. Samples withcurrent peaks lower than about 196 μA were negatively scored by CDP asneither cancerous nor pre-cancerous tissue with different types ofbenign states such as usual ductal hyperplasia, adenosis, fibrosis andnon-proliferative fibrocystic changes. Most of the abnormal samples werefound in DIN classification (as the mostly occurred types of breastdiseases such as IDC, DCIS, ADH and UDH). CDP peak responses were scoredwith a defined cut-off between free and involved margins (at 203 μA),respectively assigned as “Negative” and “positive”. Such scoring wouldconsider any pathological involvement to atypical, pre-invasive andinvasive lesions in margin checking. Also, a warning regime in negativeregions was defined in this classification. These samples with currentpeaks between about 137 μA and about 196 μA may be classified in thisregion. Surgeons need to be aware on these lesions through presence ofcomplex fibroadenoma, complex SA or single focus of atypia. Althoughthese lesions are not pathologically high risk pre-neoplasia, they oughtto be reported and considered through some guidelines. DIN1b (e.g. twoor more foci of ADH), DIN1c (e.g. low grade-DCIS), DIN2 (e.g.intermediate DCIS), DIN3 (e.g. high grade DCIS) and IDC lesions showedresponse peaks in the ranges between 203 to more than 600 μA which werepositively scored by CDP. Based on this example, pathologicallyvalidated diagnostic scores of exemplary CDP 102 were defined for 258breast tissue samples with sensitivity of about 95% and specificity ofabout 92% respectively. Such results may be achieved by CNT coveredsensing needles of exemplary CDP 102 which may provide selectiveinteraction with released H₂O₂ from abnormal tissues with no postrecording perturbation on morphology and distributions of the sterilizedCNT-covered needles.

EXAMPLE 11: REAL-TIME IN-VIVO SCORING OF EXTERNAL MARGINS (EMS) ANDINTERNAL MARGINS (IMS) BY CDP DURING BREAST CANCER SURGERY IN HUMANMODELS

In this example, exemplary prepared CDP 102 was utilized throughexemplary method 200 as a real-time diagnostic tool to find involvedbody side margins (named IMs) during human cancer surgery. In thisregard, exemplary prepared CDP 102 was applied in real-time finding ofsuspicious IMs and EMs during lumpectomy and/or mastectomy of 127patients with different types of breast tumors in different steps oftreatment. 14 patients were excluded from the survey and 113 patients(107 female and 6 male) were included. All of the tests were done underthe license of Ethics Committee with the informed consent of candidatepatients. The sensing needles (i.e., exemplary working electrode 158,counter electrode 160 and reference electrode 162) were entered into themargins up to a depth of about 4 mm and a stopping specimen was embeddedon exemplary head 166 to prevent from further entrance of the needles. Adistance between the exemplary three electrodes was about 3 mm. Hence,more than about 30 mm³ of exemplary portion of breast tissue was exposedto exemplary CDP 102 during each test. Depending on a surgeon's opinion,up to 12 breast margins (6 EMs on dissected tumor and 6 IMs in cavityside of a patient (including posterior, anterior, superior, inferior,medial and lateral) were intraoperatively checked by exemplary CDP 102for each patient. The EMs on dissected tumor were diagnosed (scored) byCDP and the tested lesions were sent for frozen pathology. Subsequently,the IMs in cavity side (in the body of the patient) were checked byexemplary CDP 102 and similarly the tested lesions were considered bystandard frozen pathology. Finally, all of EMs and IMs were diagnosed(scored) by exemplary CDP 102 and tested by frozen pathology, wereindividually evaluated by permanent pathology as reference standarddiagnosis based on pathological classifications of breast tumors. Also,when a permanent histological pattern was suspicious for pathologistbetween two different diagnoses (e.g. UDH and ADH), IHC would berecommended by her/him. Totally, 895 individual EMs and IMs were intraoperatively scored by CDP and diagnosed by pathology.

FIG. 20A shows an image resulted from frozen H&E (top-side image 2002),an image resulted from permanent H&E (middle-side image 2004), and a CVresponse recorded by exemplary CDP 102 (bottom-side image 2006) for theanterior IM of a patient (ID 18), consistent with one or more exemplaryembodiments of the present disclosure. It may be observed that real-timeCV response recorded by exemplary CDP 102 positively scored the margin,and both frozen and permanent H&E confirmed involvement of invasiveductal carcinoma for this patient.

FIG. 20B shows an image resulted from frozen H&E (top-side image 2008),an image resulted from permanent H&E (middle-side image 2010), and a CVresponse recorded by exemplary CDP 102 (bottom-side image 2012) for asuspicious margin inside the body of the patient (anterior margin ofpatient ID 46), consistent with one or more exemplary embodiments of thepresent disclosure. It may be observed that real-time CV responserecorded by exemplary CDP 102 positively scored the margin, and theremoved specimen showed negative result for malignancy in frozenanalyses meanwhile the permanent H&E showed the papillary lesion withAtypia region, which must be removed by surgeon. This example may showthe significant role of using exemplary CDP 102 for high-accurate cancerdiagnosis.

FIG. 20C shows an image resulted from frozen H&E (top-side image 2014),an image resulted from permanent H&E (middle-side image 2016), and a CVresponse recorded by exemplary CDP 102 (bottom-side image 2018) for asuspicious margin inside the body of the patient (posterior IM of thesame patient ID 46), consistent with one or more exemplary embodimentsof the present disclosure. It may be observed that real-time CV responserecorded by exemplary CDP 102 negatively scored the margin, which wasconfirmed by both frozen and permanent H&E as usual hyperplasia.

FIG. 20D shows an image resulted from frozen H&E (top-side image 2020),an image resulted from permanent H&E (middle-side image 2022), and a CVresponse recorded by exemplary CDP 102 (bottom-side image 2024) forSentinel Lymph Node (SLN) of patient ID 18, consistent with one or moreexemplary embodiments of the present disclosure. It may be observed thatreal-time CV response recorded by exemplary CDP 102 negatively scoredthe margin, whereas it was diagnosed as reactive lymphoid hyperplasia byboth H&E assays.

Regarding EXAMPLEs 10 and 11 described hereinabove, a matched clinicaldiagnostic categorization between the pathological results of the testedtissues and response peaks obtained by exemplary CDP 102 was proposedbased on pathological classification (ductal intraepithelial neoplasia(DIN), lobular intraepithelial neoplasia (LIN) and fibro epitheliallesion (FEL)) with the latest reported modifications. CDP scoringability in intra-operative margin detection was verified on more than890 human in-vivo clinical breast samples with sensitivity of about 97%and selectivity of about 94%. The ability of exemplary CDP 102 andexemplary method 200 in non-invasive and real-time diagnosis of internalmargins with pathological values (from high-risk benign to pre-invasiveand invasive cancer lesions) may make exemplary CDP 102 a distinctintra-operative tool with simple and small handheld equipment toincrease the prognostic factor of the cancer patients.

EXAMPLE 12: REAL-TIME TRACKING OF HYPOXIA GLYCOLYSIS IN CONIZATIONSAMPLES FOR CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN) DETECTION

In this example, exemplary methods 200 and 220 utilizing exemplary CDP102 were applied to precisely diagnose the cervical intraepithelialneoplasia (CIN) cells in cone biopsy samples in real-time in order toimprove pathological evaluations to find any missed CIN (I to III) orother high-risk dysplasia in cone biopsy samples. Electrochemical assaysaccording to method 220 utilizing CDP 102 were carried out on in-vitrohuman fresh cervical samples prepared from 30 patients' candidate forconization through the history of abnormal cells present in their papsmear results. CV studies were done using DC voltage, and no ACfrequency was applied. The potential was swept in the range from about−0.8 to about +0.8 V, using a scan rate of about 100 mV s. Hematoxylinand Eosin (H&E) staining was used as staining procedure inhistopathology assays. Hypoxia related H₂O₂ ionic currents from thein-vitro human fresh cervical samples prepared from 30 patients wererecorded. Hypoxia glycolysis metabolism of fresh cervical tissues wasmonitored immediately after dissection from the body (with anon-dehydrated size of up to 6 cm²). In each sample, at least threepoints on all over the tissue were recorded and inked the measuredlocations. Next, the tissues held in formalin and sent for standardpathological evaluation (dehydration, block preparation from thetissues, preparing a thin layer slide from the block, and H&E stainingof the slides). The permanent pathological diagnostic results of sampleswere carried out independently from considering the inked locations.After the declaration of pathological results, the block of samples wasre-molded and re-blocked from the surface in which the trace of inkedpoints (points tested by exemplary CDP 102) could be observable. Again,the H&E slide preparation processes were carried out, and thepathological diagnosis of inked regions was declared. This secondpathological evaluation was assumed as the reference for responsesrecorded by exemplary CDP 102.

FIG. 21 shows a visually summarized comparison between current peakvalues of recorded CV responses utilizing exemplary CDP 102 viaexemplary methods 200, and 220 for in-vivo cancer diagnosis within aliving tissue, and CIN pathological classification, consistent with oneor more exemplary embodiments of the present disclosure. Coherentresults were achieved after categorizing the values of recorded currentpeaks from the samples and comparing them with the H&E diagnosis of theinked samples. As may be observed from FIG. 21, current peak values ofthe recorded CV diagrams from the samples were categorized in threeranges of a first range 2100 assigned as being at healthy state, asecond range 2200 assigned as being at cancerous state, and a thirdrange 2300 assigned as being at a suspicious state. Among 30 samples, 9samples were non-CIN tissues (healthy tissues) including chroniccervicitis and benign flat condyloma tissues, which all showed currentpeaks in the first range 2100 as being between about 0 μA and about 115μA, and their healthy state was confirmed by H&E results as is exemplaryshown in images 2102 (Chronic cervicitis) and 2104 (flat condyloma).Nineteen samples were low grade cancerous and high-grade cancerous,including CIN I (image 2202), CIN II (image 2204), and CIN III (image2206) with neoplastic mitotic cells, in which all samples showed currentpeaks above about 145 μA within the second range 2200. By consideringthe pathology reports of tested regions utilizing exemplary CDP 102, aCIN based scoring of CV responses was proposed. The lowest cut-off forpathologists to declare a positive diagnosis of a cone biopsied samplemay be the presence of low-grade CIN I or neoplastic mitotic cells inupper layers of basal cells. The current peak of about 115 μA was thelowest value recorded for an involved sample. Hence, it was proposed asa cut-off current for positive scoring of CV recorded responses. Sampleswith current peaks in the third range 2300 between about 115 μA andabout 145 μA were assigned as suspicious samples to be cancerous beingat a gray zone, for which re-evaluation by pathology is recommended.

As described and shown hereinabove, exemplary methods 200, and 220, andexemplary CDP 102 may be utilized to lively and selectively determine avalue of H₂O₂ released from cancer or atypical cells, through reverseWarburg effect and hypoxia assisted glycolysis pathways. The determinedvalue of released H₂O₂ may be a high-accurate parameter for cancerdetection in any solid or liquid suspicious mass that may be cancerous.Although the pathology method may be a gold standard of cancerdiagnosis, it needs to prepare a lot of H&E slides to reach a perfectdiagnosis without any false negatives as well as time consumingpathology procedures. Accordingly, exemplary methods 200, and 220 andexemplary CDP 102 may be applied as a more accurate and fasterdiagnostic tool in comparison with pathology assays, or as acomplementary diagnostic tool for pathology assays in order to reachfast and accurate cancer detection.

While the foregoing has described what are considered to be the bestmode and/or other examples, it is understood that various modificationsmay be made therein and that the subject matter disclosed herein may beimplemented in various forms and examples, and that the teachings may beapplied in numerous applications, only some of which have been describedherein. It is intended by the following claims to claim any and allapplications, modifications and variations that fall within the truescope of the present teachings.

Unless otherwise stated, all measurements, values, ratings, positions,magnitudes, sizes, and other specifications that are set forth in thisspecification, including in the claims that follow, are approximate, notexact. They are intended to have a reasonable range that is consistentwith the functions to which they relate and with what is customary inthe art to which they pertain.

The scope of protection is limited solely by the claims that now follow.That scope is intended and should be interpreted to be as broad as isconsistent with the ordinary meaning of the language that is used in theclaims when interpreted in light of this specification and theprosecution history that follows and to encompass all structural andfunctional equivalents. Notwithstanding, none of the claims are intendedto embrace subject matter that fails to satisfy the requirement ofSections 101, 102, or 103 of the Patent Act, nor should they beinterpreted in such a way. Any unintended embracement of such subjectmatter is hereby disclaimed.

Except as stated immediately above, nothing that has been stated orillustrated is intended or should be interpreted to cause a dedicationof any component, step, feature, object, benefit, advantage, orequivalent to the public, regardless of whether it is or is not recitedin the claims.

It will be understood that the terms and expressions used herein havethe ordinary meaning as is accorded to such terms and expressions withrespect to their corresponding respective areas of inquiry and studyexcept where specific meanings have otherwise been set forth herein.Relational terms such as first and second and the like may be usedsolely to distinguish one entity or action from another withoutnecessarily requiring or implying any actual such relationship or orderbetween such entities or actions. The terms “comprises,” “comprising,”or any other variation thereof, are intended to cover a non-exclusiveinclusion, such that a process, method, article, or apparatus thatcomprises a list of elements does not include only those elements butmay include other elements not expressly listed or inherent to suchprocess, method, article, or apparatus. An element proceeded by “a” or“an” does not, without further constraints, preclude the existence ofadditional identical elements in the process, method, article, orapparatus that comprises the element.

The Abstract of the Disclosure is provided to allow the reader toquickly ascertain the nature of the technical disclosure. It issubmitted with the understanding that it will not be used to interpretor limit the scope or meaning of the claims. In addition, in theforegoing Detailed Description, it can be seen that various features aregrouped together in various implementations. This is for purposes ofstreamlining the disclosure, and is not to be interpreted as reflectingan intention that the claimed implementations require more features thanare expressly recited in each claim. Rather, as the following claimsreflect, inventive subject matter lies in less than all features of asingle disclosed implementation. Thus, the following claims are herebyincorporated into the Detailed Description, with each claim standing onits own as a separately claimed subject matter.

While various implementations have been described, the description isintended to be exemplary, rather than limiting and it will be apparentto those of ordinary skill in the art that many more implementations andimplementations are possible that are within the scope of theimplementations. Although many possible combinations of features areshown in the accompanying figures and discussed in this detaileddescription, many other combinations of the disclosed features arepossible. Any feature of any implementation may be used in combinationwith or substituted for any other feature or element in any otherimplementation unless specifically restricted. Therefore, it will beunderstood that any of the features shown and/or discussed in thepresent disclosure may be implemented together in any suitablecombination. Accordingly, the implementations are not to be restrictedexcept in light of the attached claims and their equivalents. Also,various modifications and changes may be made within the scope of theattached claims.

What is claimed is:
 1. An apparatus for in-vivo measuring of H₂O₂oxidation within a living tissue, comprising: an electrochemical probecomprising: a working electrode comprising a first biocompatibleconductive needle; a counter electrode comprising a second biocompatibleconductive needle; and a reference electrode comprising a thirdbiocompatible conductive needle; and an electrochemicalstimulator-analyzer comprising a potentiostat circuit, the potentiostatcircuit comprising: a control amplifier comprising a first controlinput, a second control input coupled to the reference electrode, and acontrol output coupled to the counter electrode, the control amplifierconfigured to generate a control voltage at the control output byamplifying a voltage difference between the first control input and thesecond control input; a transimpedance amplifier comprising atransimpedance output and a transimpedance input connected to theworking electrode, the transimpedance amplifier configured to generate atransimpedance voltage at the transimpedance output by amplifying avoltage of the transimpedance input; a peak detector circuit comprisinga detector output and a detector input coupled to the transimpedanceoutput, the peak detector circuit configured to: detect a maximumvoltage at the detector input in a given period of time; and transmitthe maximum voltage to the detector output; a feedback network connectedbetween the detector input and the transimpedance input; a periodic wavegenerator configured to: responsive to becoming active, generate aperiodic wave at the first control input; and responsive to becominginactive, couple the first control input to ground; and a comparatorcircuit configured to: activate the periodic wave generator by providingan activation voltage to an activation input of the periodic wavegenerator responsive to a voltage of the detector output being smallerthan a reference voltage; and deactivate the periodic wave generator byproviding a deactivation voltage to the activation input responsive to avoltage of the detector output being equal to or greater than thereference voltage, wherein the electrochemical stimulator-analyzer isconfigured to: generate a set of electrical currents in a portion of theliving tissue by applying a set of electrical potentials to theelectrochemical probe; and record the set of electrical currents bymeasuring an electric current flowing from the counter electrode to theworking electrode.
 2. The apparatus of claim 1, wherein theelectrochemical stimulator-analyzer is further configured to: apply theset of electrical potentials by applying a sweeping range of electricalpotentials between -1 V and 1 V to the working electrode; and measurethe electric currents at the working electrode after applying eachelectrical potential in the sweeping range.
 3. The apparatus of claim 1,wherein the comparator circuit comprises: a first comparator inputconnected to the detector output; a second comparator input comprisingthe reference voltage, the second comparator input coupled to a DCvoltage supply comprising a DC voltage; and a comparator outputconnected to the activation input; wherein the comparator circuit isconfigured to: provide the activation voltage to the comparator outputresponsive to a voltage of the first comparator input being smaller thana voltage of the second comparator input; and provide the deactivationvoltage to the comparator output responsive to the voltage of the firstcomparator input being equal to or greater than the voltage of thesecond comparator input.
 4. The apparatus of claim 3, wherein the secondcomparator input is coupled to the DC voltage supply via a variableresistor configured to provide the reference voltage to the secondcomparator input by transmitting a fraction of the DC voltage to thesecond comparator input.
 5. The apparatus of claim 3, wherein theperiodic wave generator comprises: a pulse wave generator configured togenerate a periodic rectangular wave; an operational amplifier (op-amp)coupled to the pulse wave generator, the op-amp comprising: a positiveinput connected to ground; a negative input coupled to an output of thepulse wave generator; and an op-amp output connected to the firstcontrol input; an RC circuit connected between the op-amp output and thenegative input, the RC circuit comprising a first resistor R₁ and afirst capacitor C₁ connected in parallel; a second resistor R₂ connectedto the negative input; a third resistor R₃ connected between the secondresistor R₂ and the output of the pulse wave generator; and a fieldeffect transistor (FET) comprising: a source connected to ground; adrain connected between the second resistor R₂ and the third resistorR₃; and a gate connected to the activation input.
 6. The apparatus ofclaim 5, wherein the first resistor R₁, the first capacitor C₁, thesecond resistor R₂, and the third resistor R₃ satisfy a set ofconditions defined by the following: R₁C₁ >100/ƒ_(pw), R₂=R₃<0.1R₁ wheref_(ps)is a frequency of the periodic rectangular wave.
 7. The apparatusof claim 1, wherein the potentiostat circuit further comprises a unitygain amplifier connected between the reference electrode and the secondcontrol input, the unity gain amplifier comprising: a first unity gaininput connected to the reference electrode; a unity gain outputconnected to the second control input; and a second unity gain inputconnected to the unity gain output; wherein the unity gain amplifier isconfigured to transmit a voltage at the reference electrode to the unitygain output by amplifying a voltage difference between the first unitygain input and the second unity gain input.
 8. The apparatus of claim 7,wherein each of the control amplifier, the transimpedance amplifier, andthe unity gain amplifier comprises a respective operational amplifier(op-amp).
 9. The apparatus of claim 1, wherein the potentiostat circuitfurther comprises a first current buffer amplifier (CBA) connectedbetween the control amplifier and the counter electrode, the first CBAconfigured to transfer an electric current flowing through the controloutput to the counter electrode.
 10. The apparatus of claim 9, whereinthe potentiostat circuit further comprises a second current bufferamplifier (CBA) connected between the transimpedance amplifier and thepeak detector circuit, the second CBA configured to transfer an electriccurrent flowing through the transimpedance output to the detector input.11. The apparatus of claim 1, wherein the potentiostat circuit furthercomprises a first analog compensator connected between the counterelectrode and the first control input, the first analog compensatorconfigured to compensate voltage variations at the counter electroderesponsive to voltage variations at the first control input.
 12. Theapparatus of claim 11, wherein the potentiostat circuit furthercomprises a second analog compensator connected between the secondcontrol input and ground, the second analog compensator configured tocompensate voltage variations at the second control input.
 13. Theapparatus of claim 12, wherein: the first analog compensator comprises afirst compensation capacitor; and the second analog compensatorcomprises a second compensation capacitor and a compensation resistorconnected in series.
 14. The apparatus of claim 1, wherein the feedbacknetwork $\frac{V_{ref}}{I_{\max}},$ comprises a feedback resistor, aresistance R_(f) of the feedback resistor equal to where V_(ref) is thereference voltage and l_(max) is an upper limit of an electric currentflowing through the detector input.
 15. The apparatus of claim 1,further comprising a sensing part, the sensing part comprising: anelectrode holder encompassing the working electrode, the counterelectrode, and the reference electrode; and a releasing buttonconfigured to release the sensing part for replacing the sensing part.16. The apparatus of claim 1, further comprising a handle, the handlecomprising: a handle head; and a switch located on the handle head, theswitch configured to: connect the electrochemical probe to theelectrochemical stimulator-analyzer; and disconnect the electrochemicalprobe from the electrochemical stimulator-analyzer.